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1. Abstract 
 
Diabetic microangiopathy is a severe complication of long term diabetes mellitus. It 
systemically affects the blood capillaries and is characterized by a thickening of their 
basal membrane as a surrogate marker for impaired microcirculation. Clinically, this 
disease can be classified into nephropathy, neuropathy and retinopathy. To get a closer 
insight into the genetic factors causing diabetic microangiopathy the expression profiles 
of a variety of genes contributing to diabetes were obtained by high throughput TaqMan 
quantitative PCR and used to generate a gene network in silicio. The final network 
comprised 37 genes and displayed the regulatory interactions of these participants. The 
network algorithm also identified a high correlation in the expression profiles of two 
candidate genes, Btf3 and Rpl3. Confirmation by immunoblotting revealed a unilateral 
pathway, in which ectopically overexpressed BTF3 protein stimulated the expression of 
RPL3 protein. Thus, Btf3 connected Rpl3 to four out of those five genes having a vast 
number of regulatory interactions. Therefore, we propose that the Btf3/Rpl3 protein pair 
can be considered potential molecular players of diabetic microangiopathy. 
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2. Zusammenfassung 
 
Diabetische Mikroangiopathie bezeichnet eine durch Hyperglykämie induzierte, 
krankhafte Veränderung der kleinen Blutgefäße. Die charakteristische Verdickung der 
kapillaren Basalmembran gilt als typisches Anzeichen der in Folge dieser Krankheit 
auftretenden, gestörten Mikrozirkulation dieser Gefäße. Diabetische Mikroangiopathie 
wird klinisch in Nephropathie, Retinopathie und Neuropathie klassifiziert. 
Zur Ursachenforschung dieser Krankheit auf molekularer, genetischer Ebene wurden 
Gene, welche mit diabetischen Mikroangiopathie in Verbindung gebracht werden, 
hinsichtlich ihres Expressionsprofiles verglichen. Diese Profile wurden mittels High 
Throughput TaqMan Quantitative PCR ermittelt und zum Design eines genetischen 
Netzwerkes in silicio verwendet. Das so entwickelte Netzwerk umfasste schlussendlich 
37 Gene und spiegelte die funktionellen Verbindungen zwischen den einzelnen 
Netzwerkpartner wider. Mit Hilfe der hierfür verwendeten Algorithmen konnten auch 
unterschiedliche Expressionsprofile der am Netzwerkdesign beteiligten Gene analysiert 
und eine hohe Korrelation im Expressionsmuster zwischen den zwei Kandidatengenen, 
Btf3 und Rpl3, identifiziert werden. Diese Verbindung wurde auf Proteinebene durch 
Immunoblotting nachgewiesen, wodurch ein unilateraler Pathway identifiziert wurde, in 
welchem überexpremiertes BTF3 Protein die Expression des RPL3 Proteins fördert. 
Zusätzlich wurde Rpl3 durch Btf3 zu vier der fünf identifizierten Schlüsselgenen des 
Netzwerkes verbunden, wodurch angenommen werden kann, das die Btf3/Rpl3 
Wechselbeziehung eine zentrale Rolle in der Entstehung und dem Fortschreiten von 
diabetischer Mikroangiopathie spielt.  
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3. Introduction 
 
3.1. The disease of interest: diabetes mellitus 
 
Diabetes mellitus refers to a metabolic disorder that is characterized by chronic 
hyperglycaemia with disorders of carbohydrate, fat and protein metabolism due to a 
lack of insulin or because of the presence of factors that oppose the action of insulin. 
Patients suffering from full blown diabetes show characteristic symptoms as thirst, 
polyuria and blurring of vision. In its most severe form a development of ketoacidosis is 
diagnosed, which can lead to stupor, coma and, in the absence of effective treatment, to 
death. In the much more common milder variants, however, chronic pathological and 
functional changes due to hyperglycemia may occur, which insidiously be present for a 
long time before clinical diabetes is diagnosed. 
Pathophysiologically and clinically diabetes mellitus can be subdivided in two types: 
Type 1 diabetes, also known as insulin dependent- or juvenile onset- diabetes, is an 
autoimmune disease affecting the insulin producing β-cells in the Langerhans’ islands in 
the pancreas. This type accounts for 10 to 15 % of all diabetes cases, and although the 
peak incidence appears in childhood and adolescence, the onset may occur at any age. 
Although there is a genetic predisposition to autoimmune destruction of the β-cells, type 
I diabetes is also related to environmental risk factors like viruses, diet or chemicals in 
people that are genetically predisposed (Watkins, 2003; World Health Organization, 
1999). 
Type 2 diabetes mellitus, also termed non-insulin-dependent or adult-onset diabetes, is 
usually diagnosed in patients over 30, although it occurs in people much younger as 
well. Pathophysiologically, type II patients suffer from impaired insulin action, since 
the cells do not longer react properly to insulin, although it is present in the blood. This 
so-called insulin resistance can be due to various cellular abnormalities. According to 
the etiological classification type II diabetes patients suffer from deficient insulin action 
and deficient insulin secretion. The first can be due to intracellular defects of glucose 
disposal, defects of insulin receptor function, different insulin structure and because of 
rare genetic disorders. A deficiency in the insulin secretion is due to defects in 
signalling as well as to a partly destruction of beta cells. Additionally environmental 
factors play a large role, e.g. obesity, an inactive lifestyle as well as wearing out beta 
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cells due to aging, all of which are high risk factors for the development of diabetes type 
II (Lindsay and Bennett, 2001). 
 
3.2 Diabetic microangiopathy 
 
A severe complication in both types of diabetes mellitus is the development of diabetic 
microangiopathy, a dysfunction concerning the small blood vessels leading to a 
thickening of the basal membrane, leaking of intravascular protein and slowing of the 
flow of blood. Clinically, this disease can be classified into nephropathy, neuropathy 
and retinopathy, thereby affecting cells of the kidneys, the nerves and the eyes (Dahl-
Jørgensen, 1998). 
Diabetic retinopathy is a disease of the eye, thereby being the number one cause of 
acquired blindness in adults. Due to microvascular damage of the retina, swelling of the 
blood vessels and leaking of fluid happens. This leads to growing of new vessels and a 
subsequent detachment of the retina (Kowluru and Chan, 2007).  
Diabetic nephropathy affects the kidneys and developed in 25 % - 30 % of all patients 
suffering from diabetes. Incipient nephropathy is characterized by a low level of 
albumin in the urine, which rises with the ongoing of the disease. Progression of 
nephropathy leads to kidney failure due to the gradual decrease in the glomerular 
filtration rate (Thorp, 2005).  
Diabetic neuropathy can be divided in several types, whereby the most common form 
of this disease is the diffuse polyneuropathy with damages of the distal peripheral 
nerves and of the autonomic nervous system. In contrast to mononeuropathies and acute 
painful neuropathies, which start from a relatively acute onset and end in the almost 
complete recovery after six to 18 months, polyneuropathies are irreversible and 
progressing with the duration of the diabetes (Watkins, 2003).   
 
Today reactive oxygen species (ROS) are proposed as the key factor that connects all 
the different pathogenic effects of diabetes on blood vessels (Du et al., 2000; Nishikawa 
et al., 2000). These ROS are produced by the mitochondrial electron transport chain as a 
result of intracellular hyperglycaemia (Figure 1). 
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Figure 1. Production of reactive oxygen species by the mitochondrial electron 
transport chain in diabetic cells. Intracellular hyperglycaemia leads to a high 
membrane potential by increase of the electron donors NADH and FADH2 (Brownlee, 
2001). 
 
The electron transport chain (Fig. 1) consist of four complexes built into the structure of 
the inner mitochondrial membrane, connected by the mobile carriers ubiquinone and 
cytochrome c. Complex I carries electrons from NADH, complex II from succinate via 
FADH2 to ubiquinone, which then delivers them to complex III. There the electrons are 
transported by cytochrome c to complex IV and finally to molecular oxygen, which they 
reduce to water. Some of the energy of the electrons is used to pump protons across the 
mitochondrial membrane, thus generating a voltage to drive ATP synthesis by ATP 
synthase. Due to intracellular hyperglycaemia more electron donors (FADH2, NADH) 
are pushed into the electron transport chain, resulting in an increase of the voltage 
gradient. By reaching a critical threshold value the electron transfer inside complex III 
is blocked, the electrons return to ubiquinone and are donated to molecular oxygen thus 
generating superoxide, a reactive oxygen species (ROS) (Korshunov et al., 1997). These 
molecules contribute to diabetic pathologies by inhibiting the activity of the key 
glycolytic enzyme glyceraldehyd-3 phosphate dehydrogenase (GADPH). This 
inhibition is achieved by a mechanism where ROS induce DNA strand breaks, thereby 
activating the DNA repair enzyme poly (ADP-ribose) polymerase (PARP) that splits 
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NAD+ into nicotinic acid and ADP-ribose. The latter is then converted to long polymers 
that accumulate on GAPDH, thereby inactivating this enzyme and leading to the 
activation of four major pathways of diabetic damage (Brownlee 2001; Brownlee 2005): 
 
 
3.2.1. Increased polyol pathway flux 
 
In the polyol pathway the enzyme aldose reductase catalyses the NADPH dependent 
reduction of carbonyl compounds like toxic aldehyds to inactive alcohols. Under 
diabetic conditions when glucose level gets too high, aldose reductase also reduces 
glucose to sorbitol, which then became oxidized to fructose by sorbitol dehydrogenase 
with NAD+ reduced to NADH.  
During this process of the aldose reductase, the cofactor NADPH is converted to 
NADP+. This process reduces the amount of reduced glutathione, an important 
intracellular antioxidant, which leads to an increased susceptibility of the polyol 
pathway to intracellular oxidative stress (Lee and Chang, 1999).  
 
 
3.2.2. Intracellular production of advanced glycation end products 
 
AGEs precursor molecules alter cellular function in three different ways. First, it 
modifies intracellular proteins which results in an altered function, e.g. in transcription 
(Giardino et al., 1994; Shinohara et al., 1998). Second, AGEs modify the extra cellular 
matrix leading to cell dysfunction. This mechanism involves modifying of plasma 
proteins by AGE precursors, which then bind to AGE receptors e.g. on macrophages, 
resulting in production of inflammatory cytokines and growth factors as well as 
activation of the transcription factor NF-κB, leading to changes in gene expression of 
growth factors and cytokines (Doi et al., 1992; Skolnik et al., 1991). 
 
 
3.2.3. PKC activation 
 
Protein kinase C, a cyclic nucleotide independent protein kinase, is primarily activated 
by the lipid second messenger diacylglycerol (DAG). The amount of DAG is increased 
by intracellular hyperglycaemia, thereby leading to activation of the PKC isoforms β 
and δ (Koya and King, 1998; Xia et al., 1994). This process activates NF-κB and 
NAD(P)H oxidases (Yerneni et al., 1999) and alters the gene expression of endothelial 
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nitric oxide synthetase (eNOS), endothelin-1 (ET-1), vascular growth factor (VEGF), 
transforming growth factor –β (TGF-β) and plasminogen activator inhibitor-1 (PAI-1), 
thereby contributing to blood flow abnormalities, vascular permeability, angiogenesis, 
capillary and vascular occlusion and pro-inflammatory gene expression (Kuboki et al., 
2000) .   
 
 
3.2.4. Increased hexosamine pathway activity 
 
If intracellular glucose rises up to a high level it gets metabolized by glycolysis, 
resulting in the formation of pyruvat and NADH as well as ATP (Brownlee, 2001). 
Small amounts of the glycolytic intermediate fructose-6-phosphat do not enter the 
glycolytic pathway, but get sidetracked into the hexosamine signalling pathway, where 
fructose-6-phosphat is converted to uridine diphosphat N-acetylglycosamine (Wells and 
Hart, 2003). These products modify threonine and serine residues of transcription 
factors such as Sp1, resulting in altered gene expression of transforming growth factor-
β1 and plasminogen activator inhibitor-1, thus affecting diabetic blood vessels (Du et 
al., 2000).  
 
Inhibition of GADPH leads to an increase of glycolytic intermediates like 
glyceraldehyde-3-phospate, fructose-6-phospate as well as glucose itself. The major 
intracellular AGE precursor methylglyoxal as well as diacylglycerol DAG are formed 
from glyeraldehyd-3 phosphate, thereby contributing to the AGE and the PKC pathway. 
Fructose-6 phosphate increases the flux through the hexosamine pathway and an 
increase of intracellular levels of glucose activates the polyol pathway (Brownlee 2001) 
(Fig.2).   
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Figure 2. Inhibition of GADPH by ROS overproduction leads to activation of four 
major pathways of diabetic pathologies. For detailed description see above (Brownlee 
2001). 
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3.3. Translation 
 
Translation is next to transcription one of cells most important processes. Ribosomes 
convert genetic information of mRNA into amino acids, thereby forming chains of 
polypeptides and proteins. These features reside in two ribosomal subunits. Of these, the 
smaller one performs the decoding function, thereby mediating interactions between 
tRNA and mRNA to determine the order of amino acids composing the synthesized 
protein. The large particle contains the peptidyl transferase centre (PTC), the active site 
of the ribosome where the formation of the peptide bonds occurs. Therefore the function 
of the large ribosome subunit is to catalyse the peptide bond formation. Both ribosome 
subunits contain three binding sites for tRNAs: Whereas the A site binds aminoacetyl-
tRNA that is going to be incorporated into the growing peptide chain, the P site binds 
peptidyl-tRNA, and at the E site deacylated-tRNAs are bound before they dissociate 
from the ribosome (Lafontaine and Tollervey, 2001). Translation itself can be 
subdivided into three main parts, initiation, elongation and termination. Initiation is one 
of the most extensively studied and rate limiting steps in the whole translation process. 
It starts with binding of a binary complex (eukaryotic translation initiation factor 2 
(eIF2) and GTP) to methionyl-transfer RNA (Met–tRNAMet), thereby forming a ternary 
complex that associates with the 40S ribosomal subunit. Binding of additional factors 
(eIF3, eIF1A) facilitates this interaction and creates a 43S preinitiation complex. Next 
the cap binding complex, consisting of eIF4E, eIF4G (a scaffold protein) and eIF4A (an 
RNA helix), binds to the 7-methyl-GTP cap structure of a mRNA, thereby bridging the 
5’ and 3’ ends of the mRNA by simultaneously binding of elF4G to the poly(A)-binding 
protein PABP. The 48S pre-initiation complex is formed by binding of the 43S pre-
initiation complex to the mRNA. This process is promoted by the ATP-dependent 
helicase activity of eIF4A as well as by the circulation of the mRNA. Next the ribosome 
is scanned for the AUG start codon. The initiation factors that participate in translation 
are released after the formation of the 48S initiation complex and are recycled for 
another round of initiation. This release is assisted by eIF5, which facilitates the 
hydrolysis of GTP carried by eIF2 and, hence, the dissociation from of the 48S 
complex. Finally, the large 60S subunit is bound in a eIF5B- and GTP-dependent way, 
thereby forming the 80S initiation complex, which triggers elongation and protein 
synthesis (Holcik and Sonenberg, 2005; Klann and Dever, 2004).  
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During the elongation step peptide bond formation and mRNA decoding takes place. 
Nascent polypeptides are extended from the A to the P site of the ribosome by adding 
one amino acid at a time. This reaction is catalyzed by the elongation factor eEF1 and 
eEF2 and starts with an interaction between anticodon of tRNA with the analogous 
codon of the mRNA at the A-site. The correct codon-anticodon pairing activates the 
GTPase centre that is located in the large subunit and results in hydrolysis of the eEF1 
GTP complex, release of eEF1 from the ribosome, accommodation of the aminoacyl 
end of the tRNA into the PTC and peptide bond formation. This reaction is catalyzed by 
the enzyme peptidyltransferase, a ribozyme that is located on the large ribosomal 
subunit. Subsequent translocation of the ribosome in 3´mRNA direction to decode the 
next mRNA codon is catalyzed by binding to eEF2, a GTPase that facilitates the shift of 
the deacylated tRNA from the P-site to the E-site and of the peptidyl-tRNA from the A 
site to the P-site upon GTP hydrolysis (Steitz 2008). 
 
 
 
Figure 4. Peptid bond formation and peptidyl-tRNA hydrolysis. (A)In the first 
reaction, the α-amino group of aminoacyl tRNA in the A-site attacks the carbonyl 
carbon of the peptidyl tRNA in the P site, resulting in deacylated tRNA at the P-site and 
peptidyl-tRNA with an additional amino acid at the A-site. (B) Peptide release starts 
with a nucleophillic attack of the peptidyl-tRNA by activated water, leading to peptidyl-
tRNA hydrolysis and polypeptide release (Polecek and Mankin, 2005).  
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Peptid bond formation itself starts with a nucelophillic attack on the carbonyl carbon on 
the peptidyl-tRNA by the α-amino group of the aminoacyl-tRNA, leading to the 
acetylation of the 3´-hydroxyl group of the peptidyl-tRNA and the formation of a 
tetrahedral intermediate at the carbonyl carbon (Fig. 4) (Polacek and Mankin, 2005). 
Resolving of the intermediate results in a peptide, that is extended by one amino acid, 
esterifies to the A-site-bound tRNA and a deacylated tRNA in the P-site (Lafontaine 
and Tollervey, 2001). Besides peptide bond formation, the PTC carries out peptidyl-
tRNA hydrolysis, which is required for termination of translation and subsequent 
release of the assembled polypeptide of the ribosome. This reaction starts with a 
nucleophillic attack of an activated water molecule on the carbonyl carbon of the 
peptidyl-tRNA ester, leading to peptidyl-tRNA hydrolysis and subsequent polypeptide 
release (Fig.3) (Polecek and Mankin, 2005).  
After eEF2-GDP release, the ribosome is ready for a next round of elongation until a 
stop codon in the mRNA reaches the A site at the end of the elongation circle, thereby 
starting termination of translation. The activity of termination factor eRF-1 (eukaryotic 
release factor 1) is triggered by eRF-3, a GTP binding protein. eRF3 complexes with 
eRF-1, thereby permitting binding to the stop codon and leading to ester bond cleavage 
between peptide and pepdityl-tRNA, and the subsequent release of new protein. GTP 
hydrolysis enables releasing of the termination factors, thereby permitting the ribosome 
to start a new translation cycle (Steitz 2008). 
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Figure 3. Eukaryotic translation initiation. Initiation of translation starts by forming 
the 43S pre-initiation complex. RNA circulation by association of the cap binding 
complex with Poly A binding protein leads together with the 43S protein complex to 
formation of the 48S pre-initiation complex. Initiation is finished by adding the 60S 
subunit to the growing particle, thereby forming the 80S initiation complex. (Klann and 
Dever, 2004). 
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3.4. Ribosomes 
 
Ribosomes are highly conserved ribonucleoprotein particles that participate in protein 
synthesis and are made up of RNA and ribosomal proteins. Eukaryotic ribosomes 
sediment at 80S and as mentioned above are divided into a 60S, containing the 28S, 
5.8S, 5S RNAs and 49 proteins, and a smaller 40S subunit which consists of the 18S 
RNA and 33 ribosomal proteins (Lafontaine and Tollervey, 2001) 
 
3.4.1. Structural analysis of the large ribosomal subunit 
 
Crystal structure analysis of ribosomal proteins of the halophilic archeon Haloarcula 
marismortui (Ban et al., 2000) and the eubacteria Escherichia coli (Vila-Sanjurjo et al., 
2003) allows a deeper insight into ribosomal protein structure and their interactions with 
RNA (Fig. 5). Due to the universal conservation of ribosome features and the similarity 
between archaeal and bacterial subunit structures, these finding could be also applied on 
eukaryotic structures (Korostelev and Noller, 2007). The main functions of the large 
subunit comprise binding of tRNA, catalysing peptidyl transfer and performing 
translocation.  
Before the complete subunit structures were published, it was not clear, if the multiple 
tasks of the ribosome were performed by RNA alone or if ribosomal proteins also 
contributed to these functions. Structure analysis identified the ribosome as a ribozyme, 
where RNA carries out the catalytic function. Nevertheless, some proteins are still 
connected with ribosomal features (Brodersen and Nissen, 2005). 
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Figure 5. Structure of the 50 S ribosomal subunit of Haloarcula marismortui in (a) 
crown view, (b) back view and (c) bottom view. The sugar phosphate backbone of 23 
S and 5 S RNAs are coloured in red, bases in grey. Ribosomal proteins are illustrated as 
yellow α-carbon ribbons (Klein et al., 2004). 
 
 
The main function of ribosomal proteins is the stabilization of interdomain interactions 
of RNA, since most proteins bind several sites of the seven RNA domains of the large 
subunit, even if they are far separated in the sequence. Although the proteins of the 
large subunit seem to be regularly scattered, two regions with a denser distribution were 
identified: First, the upper right side of the particle that binds to translation factors and 
contains the ribosomal proteins L3, L6, L10, L11, L12, L13 and L14. The second region 
with higher protein concentration surrounds the distal end of the polypeptide exit tunnel 
and includes L19e, L22, L23, L24, L29, L31e, and L39e. Another important feature 
found in the large subunit is the widespread RNA surface area that is buried by r-
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proteins, mostly due to the fact that these proteins contain extensions that reach deep 
into the RNA core of the ribosome. These idiosyncratically folded polypeptides form 
three dimensional structures with distinct amino acid composition, consisting mostly of 
glycine-, arginine-, and lysine residues. In contrast to the globular domains, the content 
of acid residues is rather low in the extensions, coming along with the fact that globular 
domains are found on the exterior, whereas the extensions reaches the interior of the 
ribosomal particle. The negatively charged RNA backbone of the core is therefore 
neutralized by basic residues of the extensions, allowing correct rRNA folding. Due to 
structural topology of the globular domain the ribosomal proteins were classified into 
the following six groups: The antiparallel α + β group (L5, L6, L10e, L15e, L22, L23), 
the β-barrel group (L2, L3, L14, L21e, L24), the zinc containing group (L24e, L37Ae, 
L37e, L44e), the α-helical group (L19e, L29, L39e), the L15 group (L15, L18e) and the 
mixed α + β group (L4, L7Ae, L13, L18, L30, L31e, L32) (Klein et al., 2004). 
Since ribosomes are made up of protein and RNA, interactions between these two 
components were an important part of structure analysis. Hence four ways were found 
how these interactions in the large subunit were achieved: Hydrogen bonds with 
nucleotide bases via the minor groove and the major groove, protein recognition of the 
flipped out bases of bulged nucleotides and hydrophobic interactions of amino acid 
residues with crevices between the bases contributed to RNA stabilizing. Interactions 
between the various ribosomal proteins were also observed, although the average 
contact surface of protein interactions was much smaller than between proteins and 
RNA. Still, the proteins L37Ae, L24e and L7Ae participate in protein interactions that 
appear to be of greater importance than their RNA correlation (Klein et al., 2004). 
 
 
3.4.2. The ribosomal protein of the large subunit 3 
 
RPL3, a 44 kDa ribosomal protein of the large subunit, whose gene is located on the 
q13 of chromosome 22. Furthermore, it is one of the proteins that bury the largest RNA 
surface area due to their protein extensions. The archael and eukaryotic ribosomal 
protein L3 contains 2 extensions, one being positioned at the N terminus, the other 
reaching deep into the core of the large subunit. The latter is also referred as tryptophan- 
or W-finger, since this extension projects to the A site side of the PTC and a 
tryphtophan at the tip of the finger approaches to the active site of the peptidyl 
transferase centre (PTC). Furthermore, two important rRNA helical structures were 
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anchored at this site, helix 95, that forms the sarcin-ricin loop, an important recognition 
site for translation elongation factors, and the structures formed by helices 90 – 92. The 
latter takes part in accommodation, the movement of aminoacyl tRNA from the partially 
bound “A/T” state to the fully bound “A/A” state, by forming together with helix 89 the 
corridor, through which 3´ends of aa-tRNAs slide. Beside the mentioned polypeptides 
finger, RPL3 includes 2 globular domains, whereas one harbours a β-barrel group 
structure that resembles domain II of the translational GTPases EF-Tu and EF-G. The 
second globular domain of RPL3 has an antiparallel α + β domain structure. The 
mentioned domains bind H95 and H96 and are positioned near helices 94 and 96, 
thereby flanking the sarcin/ricin loop (SRL), the side of ribosome interaction with the 
elongation factors eEF1 and eEF2. Interactions of these domains with RNA stabilize 
tertiary folding of the domain IV of the large subunit, therefore facilitating ribosome 
function. (Klein et al., 2004; Irvin and Uckun, 1992; Sanbonmatsu et al., 2005; 
Meskauskas et al., 2005) 
 - 21 -
 
 
 
Figure 6. Ribosomal protein L3 and its interaction with RNA. The protein is 
displayed as green ribbons, the sugar phosphate backbone of RNA is illustrated in red 
and magenta, bases in grey. RPL3 interacts with RNA by major and minor groove 
special base recognition, specific protein binding pockets and amino acid residues. 
(Klein et al., 2004).  
 
For RNA interactions of the RPL3 protein, specific base recognition through the major 
and minor groove, specific protein binding pockets as well as interactions due to 
insertion of amino acid residues into hydrophobic crevices between bases were 
observed (Fig. 6). Groove binding was mostly achieved by Watson Crick base pairing, 
although wobble base pairing and non canonical interactions were also detected. 
Additionally, RPL3 interacts with RPL13 and RPL14, thereby burying a total surface 
area of 7.3 %. (Klein et al., 2004) 
Another important feature of RPL3 is its role in initiating subunit assembly. Next to 
L24, RPL3 is the only ribosomal protein that is able to initiate in vitro assembly of 
E.coli´s large subunit. Although the globular domain interacts only with domain VI, the 
extensions pass between the domains II, III, IV, V and VI, but not to domain I, that 
contains the entire RPL24 binding site, suggesting the roles of these two proteins in 
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subunit assembly being distinct and independently from each other (Spillmann et al., 
1977; Nowotny and Nierhaus, 1982). 
Given the fact that ribosomal proteins are too far away from the PTC to participate 
directly in its actions, RNA was identified as the main source of catalysing the PTC 
activity (Lafontaine and Tollervey, 2001; Steitz, T.A. 2008; Spirin A.S. 2004). 
Nevertheless, ribosomal proteins were still considered to contribute to ribosome 
associated functions (Meskauskas et al., 2005). Recently a new model was proposed, in 
which RPL3 acts as a “rocker switch” to organize translational elongation, thereby 
coordinating the functions of SRL and PTC. In the open conformation the helices 89, 
90-92 and 95 are positioned, that they are able to form a binding site for the aa-
tRNA•eEF1A•GTP ternary complex. In this state, the W-finger is in the “extended” 
conformation and occupies with its tip the A-site of the PTC. Interaction with the 
25SrRNA stabilizes this status. At the same time, the N-terminal extension is in the 
retracted conformation, thereby opening the corridor. Accommodation of the aa-tRNA 
at the A-site triggers the opening of this site and retraction of the W-finger, followed by 
rotation of the globular domain of RPL3 and extension of the N-terminal domain 
towards helix 89. The displacement of helix 91 leads to the closure of the 
accommodation corridor and repositioning of the H90/H92 structure and from 25S 
rRNA in the A site permits interaction with aa-tRNA, thus activating peptidyltransfer. 
Finally, the movement of H91 away from H95 leads to formation of the eEF2-binding 
site (Meskauskas and Dinman, 2007; Meskauskas and Dinman, 2008) (Fig. 7). Taken 
together, these findings indicate a new role of RPL3 in translational elongation. 
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Figure 7. Model of RPL3 acting as a rocker switch in peptidyltransfer. In the 
ground state is the P site occupied by the peptidyl –tRNA, the W finger of RPL3 in the 
extended conformation, thereby maintaining the A site in the closed conformation. 
When the L3 N-terminal extension is in the retracted confirmation, the accommodation 
corridor opens, thereby leading to opening of the A site and retraction of the W finger, 
rotation of RPL3 globular domain, extension of the N-terminal domain toward Helix 89, 
displacement of Helix 91 and finally closure of the accommodation corridor. 
Peptidyltransfer is activated by reposition of H91/H92 structure and of G2921 in the A 
site, where an interaction with C75 of aa-tRNA could occur. The formation of the eEF2 
binding site is achieved by movement of H91 away from H95 (Meskauskas and 
Dirnman, 2007). 
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3.5. BTF3 
 
BTF3, the basic transcription factor 3, also known as RNA polymerase transcription 
factor 3 and nascent-polypeptide associated complex beta polypeptide, gives rise to the 
two splicing variants BTF3a and BTF3b, whereas the latter is an N-terminally truncated 
version that is shortened by 44 amino acids (Zheng et al., 1990; Kanno et al., 1992). 
Due to the fact that BTF3 binds to RNA polymerase II, this gene was believed to be 
essential for RNA polymerase II-dependent transcriptional initiation, although its role as 
transcription factor is still discussed (Zheng et al., 1987). Additionally, BTF3 protein 
was identified as part of the nascent-polypeptide-associated complex (NAC), a 
heterodimeric complex that can bind to eukaryotic ribosomes (Wiedmann et al., 1994). 
The NAC consist of a α subunit and a BTF3 encoded β-subunit, whereas both splicing 
variants of the beta subunit (BTF3a, BTF3b) form stable complexes with α NAC. Both 
subunits are located in close proximity to ribosome bound nascent polypeptide chains, 
and binding to nascent chains happens ubiquitously in a distance of 17 to 100 amino 
acids from the PTC, thereby taking part in cotranslational targeting of polypeptides to 
the endoplasmic reticulum (ER). Generally, protein translocation to the ER involves 
next to NAC, SRP, a cytosolic ribonucleoprotein complex that recognises a special 
signal sequence on the N-terminus of proteins. At the lipid bilayer, the signal sequence 
is additionally recognized by the Sec61 complex and leading to translocation of nascent 
polypeptides into the lumen of the ER (Rospert et al., 2002; Wickner, 1995).  
Beside these described functions, BTF3 plays also a key role during initiation of protein 
synthesis. As already mentioned, translation initiation requires forming of the 43S pre-
initiation complex (eIF2•GTP•Met-tRNA•40S ribosomal subunit) and binding it to the 
mRNA, a step that is promoted by the cap-binding complex eIF4F. This heterotrimeric 
complex is constituted of the cap-binding protein eIF4E, an RNA helicase and ATPase 
(eIF4A) and eIFG4, the scaffolding protein with binding site for PABP and ribosome 
associated factors. Two plant homologs of mammalian eIF4E interact with BTF3. The 
involved amino acid motif, RLQSTLKRIG, is part of the first 101 amino acids of BTF3 
and interacts with a consensus motif that can be found on most of the 4E-binding 
proteins. This suggests a dual function of BTF3 in translation initiation as well as in 
elongation by acting on nascent polypeptide chains (Freire, 2005; Beatrix et al., 2000). 
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3.6. Genetic Networks 
 
Most experimental understand cellular functions are based on a minimization, meaning 
that identification of certain structures and functions all the complex interactions of a 
living cell are put aside. Therefore all these attempts represent only a part of complex 
cellular processes, since distinct biological functions cannot be attributed to single 
molecules. Instead they come up from complex relations between all the cells 
components like proteins, DNA, RNA and small molecules. To understand these 
multipart interactions that contribute to cells function and structure is one of the major 
tasks in biology. Due to the development of high-throughput genomics it is now 
possible to determine when and how all these molecules interact with each other, thus 
generating regulatory networks instead of isolated linear pathways (Barabási and Oltvai, 
2004). So the focus has switched from one particular process to a more global view. 
Generally, these molecular networks can be divided into three types: 
A metabolic network is the complete set of metabolic and physical processes in a living 
cell that determine it’s physiological and biochemical properties. These networks 
comprise the chemical reactions of metabolism as well as the regulatory interactions 
that guide these reactions (Ma and Zeng, 2003). Transcriptional networks describe the 
relationship between pairs of genes, comparing the effect of the expression level of one 
gene on the expression level of the other one (Ronen et al., 2002; Evangelisti and 
Wagner, 2004). Protein interaction networks represent the relationship between 
different proteins such as forming complexes or modifications by signalling enzymes 
(Uetz et al., 2000; Maslov and Sneppen, 2002; Agrafioti et al., 2005) Even this 
classification is just a simplified version of the complex processes going on in the living 
cell since these networks are in reality highly connected: Gene expression always 
depends on the level of proteins as well as on metabolites, so there are some feedback 
loops between these systems demonstrating that regulation is a principle feature of 
biological systems (de Silva and Stumpf, 2005). Therefore these highly interconnected 
systems are referred as democratic, while hypothetical systems without feedback 
regulation are called dictatorial (D. Stokic, personal communication). 
Networks themselves are complex systems, whose components communicate with each 
other through pairwise interactions, which can be reduced to a pair of nodes that are 
connected to each other by links. Links and nodes together form a network, or in 
mathematical terms, a graph. Complex networks can be charcaterised according to their 
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degree or connectivity k that defines the number of links between nodes. In contrast to 
undirected networks, in directed networks it can be distinguished between incoming and 
outgoing degrees. The first mentioned refers to the number of links that are directed to a 
node (kin), whereas kout refers to the number of links that start from a node. The degree 
distribution P(k) refers to the probability, that selected nodes contain the connectivity k, 
and enables to characterize different networks. Furthermore, important information like 
the existence of highly connected nodes (hubs) in a network could be derived out of 
degree distribution. Another notable class of networks are scale-free ones, which have a 
power law degree distribution, P(k) ~ k−γ, where γ is the degree exponent, that is 
inversely proportional to the importance of the role of the hubs in the network. Most 
processes within the cell contain a scale-free topology, like protein-protein-, and genetic 
regulatory networks, in which the nodes represent single genes and links are derived 
from perturbation experiments (Barabasi and Oltvai, 2004; Jeong et al., 2000; Wagner 
and Fell, 2001).  
Shortest path and mean path lengths are important for network distances. The first refers 
to the number of links that have to be passed to travel between two nodes and the mean 
path length represents the average over the shortest paths between all pairs of nodes. 
The last measure needed for network topology is the clustering coefficient, CI = 2nI / 
k(k-1), which quantifies how close a node and its neighbours are to being a cluster. 
Otherwise put, if node A is connected to node B, and node B is connected to node C, 
then the clustering coefficient indicates the possible connection of node A to node C 
(Barabasi and Oltvai, Watts and Strogatz, 1998). 
 
3.6.1. Network identification by multiple regression 
 
In 2003, Gardner et al. developed algorithm that enables to represent complex 
biological connections in a gene regulatory network. Based only on steady-state 
expression measurement, a functional and predictive model of gene interactions could 
be constructed. Therefore a system identification method, called network identification 
by multiple regression (NIR) that comprises the response of genes and proteins to 
external perturbations, was applied. It was assumed, that such genetic networks can be 
described by nonlinear regression equations. Furthermore, near the steady–state, when 
gene expression does not change over time, a nonlinear system can be described by 
linear equations, where the rate of accumulation of RNA, protein or metabolite results 
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from a transcriptional perturbation. Out of these presumptions, the following formula 
was developed: 
 
dx/dt = Ax + u 
 
x…concentrations of N RNA-species  
dx/dt…rate of accumulation of species x 
u…external perturbations 
A…N x N matrix, describing the regulatory interactions between the species in x 
 
Under steady-state expression (dx/dt = 0), A can be solved by performing N distinct 
perturbations (u) and recovering N sets of RNA concentrations (x). Due to high levels 
of background noise, measurement of mRNA levels leads to wrong data. By applying a 
simplified model that rests on the fact that biological networks are not fully connected, 
the equation could be solved by assuming a maximum of k (where k<N) non-zero 
regulatory inputs to each gene, thus generating a robust system. Finally, multiple linear 
regression was used to select k in a way, that the final system is stable and the resulting 
coefficient of A is statistically significant (Gardner et al., 2003) 
 
The NIR method was adapted on a subnetwork of the SOS pathway in E.coli, resulting 
in identification of most of the gene connections. Nevertheless, only nine transcriptional 
perturbations were applied, so that the effects and the applicability of larger networks 
on the identified algorithm were unknown. To overcome this limitation, the Complex 
System Research Group, Medical University of Vienna, developed further algorithm, 
which considers the features of larger networks with at least 30 transcriptional 
perturbations. Therefore the original equation dx/dt = f(A, x) was expanded in following 
ways: 
 
A= ln (D+I)  
 
  
A....adjacency matrix 
D....influence matrix 
I…..identity matrix  
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In order to describe the regulatory interactions in a network, the adjacency matrix has to 
be solved. Therefore, the influence matrix, Dij ,= ln (xij/xi0) was determined. The term xij 
/xi0 refer to the gene expression of ith gene, if the jth gene is perturbed, whereas xi0 stands 
for gene expression of the ith gene with the empty vector. Therefore, the influence 
matrix describes the effect of perturbation of one gene to the expression of another 
gene. The results of (xij/xi0) are always <1, 0, or >1, indicating positiv-, negativ- or no 
interaction at all. The network consists of matrices for each possible path, and can 
finally be determined by summing up all matrices. Since D is also referred as function 
of all paths in a network, the adjacency matrix A can finally be calculated by the quoted 
equation. (D. Stokic, personal communication)  
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4. Materials and Methods 
4.1 Buffers and Solutions 
 
 
Luria Broth agar plates 
7.00 g Bacto-tryptone (DIFCO, USA, Cat.No. 211705) 
3.50 g Bacto-yeast extract (DIFCO, USA, Cat.No. 212750)  
7.00 g NaCl 
10.5 g Agar (DIFCO, USA, Cat.No. 281230) 
Distilled water was added to a volume of 700 ml, pH 7,5 (adjusted using 1N NaOH), 
Medium was autoclaved, cooled down to 50°C  
700 µl antibiotics were added (30µg/µl ampicillin, chloramphenicol or kanamycin). 
 
 
50 x TAEBuffer 
96.80 g TRIS 
22.80 ml CH3COOH 
40.00 ml EDTA (0,5M) 
Distilled water was added to a volume of 20 l. 
 
 
Plasmid Preparation Lysis Buffer (TENS) 
0.50 ml 1 M TRIS 
100 µl  0.5 M EDTA 
5.00 ml 1N NaOH 
1.15 ml 20% SDS 
Distilled water was added to a volume of 50 ml. 
 
 
SOC Medium 
  5.0 g Bacto-yeast extract (DIFCO, USA, Cat.No. 212750) 
20.0 g Bacto-tryptone (DIFCO, USA, Cat.No. 211705)  
  0.5 g NaCl,  
10.0 ml 0.25 M KCL  
  5.0 ml 2 M MgCl2 
20.0 ml 1 M D-glucose 
Distilled water was added to a volume of 1000 ml, pH adjusted to 7.0. 
 
 
 
 
 
 
 
 
 
LB medium 
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1 x Laemmli Buffer 
6.25 ml 1M Tris-HCl pH 6,8 
2.35 g SDS 
1.54 g DTT 
0.04 g EDTA 
10 ml Glycerol 
1 mg Bromphenol Blue 
Distilled water was added to a volume of 100 ml 
 
 
PBS (phosphate buffered saline)  
0.20 g KCl 
0.20 g KH2PO4 
1.15 g Na2HPO4 
8.00 g NaCl 
Distilled water was added to a volume of 1000 ml and pH was adjusted to 7.4 
 
 
1 x Cell Lysis Buffer  
40 μl 1 M Tris-HCl pH 8.0 
77 μl  4 M NaCl 
10 μl 50 mM EDTA 
10 μl 50 mM EGTA 
20 μl Nonidet® P40 (Fluka, Cat.No. 94385) 
20 μl 100 mM Na3VO4 
2 μl 1 M Pefabloc  [4-(2-Aminoethyl)benzenesulfonylfluoride.HCl] (Pentapharm Ltd., 
Germany, Cat.No.31682.01) 
Distilled water was added to a volume of 2 ml 
 
 
10 % SDS-Acrylamid Gel 
4.0 ml Aqua dest. 
3.3 ml 30 % Acrylamid BIS (29:1, BioRad) 
2.5 ml Tris-HCl pH 8.8 
ml 10 % SDS 
0.1 ml 10 % APS 
4 μl TEMED (N,N,N',N'-Tetramethylethylenediamine) 
 
 
Stacking Gel 
3.4 ml Aqua dest. 
830 μl 30 % Acrylamid BIS (29:1) 
630 μl Tris-HCl pH 6.8 
50 μl 10 % SDS 
50 μl 10 % APS 
5 μl TEMED 
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Electrophoresis Buffer 
72 g Glycin 
15 g Tris 
25 ml 20 % SDS 
Distilled water was added to a volume of 2.5 l 
 
 
Transfer Buffer 
28.0 g Glycin 
6.1 g Tris 
500 ml Methanol 
Distilled water was added to a volume of 2.5 l 
 
 
Ponceau S Red 
0.1 % Ponceau S Rot in Aqua dest. 
5 % Acetic Acid 
 
 
10 x TBS  (Tris Buffered Saline) 
24.5 g Tris 
80.0 g NaCl 
Distilled water was added to a volume of 1 l, pH was adjusted to 7.6 
 
 
Washing Buffer 
10 ml 10 x TBS 
90 ml distilled water 
 1 ml Tween-20 
 
 
Blocking Buffer 
5 ml 10 x TBS 
45 ml distilled water 
2.5 g nonfat dry milk 
50 μl Tween-20 
 
 
Antibody Dilution Buffer 
2 ml 10 x TBS 
18 ml distilled water 
1 g BSA 
20 μl Tween-20 
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Citrate working solution 
18 ml 0.1 M citric acid solution  
(21 g citric acid, monohydrate, in 1000 ml H2O) 
82 ml 0.1 M sodium citrate solution 
(29.4 g trisodium citrate dehydrate in 1000 ml H2O) 
Distilled water was added to a volume of 1 l, pH was adjusted to 6 
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4.2. Molecular Biology 
 
Vectors containing the coding sequence of the gene of interest were purchased from the 
German Resource Centre for Genome Research RZPD, www.rzpd.de (Fig. 7). 
 
 
 
 
 
Figure 8. Expression vectors pCMV-Sport6 and pOTB7. Vectors containing the 
coding sequence of genes of interest were ordered at the German Resource Centre of 
Genome Research RZPD and delivered as vector containing E.coli`s in step agar.  
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E. coli transformed with a vector containing the gene of interest were picked from LB 
plates to inoculate 4 ml of LB Medium, supplemented with 4 µl of antibiotics (ampilicin 
100 µg/µl, chloramphenicol 30 µl/µg, kanamycin 25 µl/µg ) according to the vector 
resistance. Before harvesting, cells were incubated on a shaker (250 rpm, 37°C) for 20 
hours. 
 
Plasmid minipreparation (DNA yield up to 20 µg) was done according to method 
“Genevieve” as well as minipreparation with the QIAprep™ Spin Miniprep Kit. The 
latter is used to obtain high purity DNA for subsequent sequencing of positive clones 
verified by digestion and gel electrophoresis. DNA yield of minipreparation  
Method “Genevieve” starts with centrifugation of 1.5 ml suspension at 9.300 x g. 
Afterwards the cells were resuspended in 40 µl supernatant, 300 µl TENS was added 
and mixed by vortexing. 150 µl ice cold KAc (3M) was added subsequently and tubes 
were inverted, followed by spinning at 10,000 rpm for 2 min. Then the supernatant was 
placed into a new tube, 900µl ethanol (96%) added and stored for 30 min at -80 °C. 
After spinning (20 min, 9,500 x g, 4°C), the DNA pellet was washed with 70 % ethanol 
and centrifuged again for 2 min at 13,000 rpm. The ethanol was removed, the pellet air 
dried and finally dissolved in 50 µl DNase-free water. 
 
Plasmid isolation using QIAprep™ Spin Miniprep Kit was initiated with centrifugation 
of 1.5 ml cell suspension at 9,300 x g. The resulting cell pellet was worked up according 
to protocol. Finally the isolated plasmid DNA was dissolved in 30 µl DNase-free water. 
 
For PCR amplification of the coding sequence (cds) of the purchased clone a Gene 
Amp 9600 System from Perkin Elmer was used and the amplification was done 
according to a standard protocol 
 
H2O   32. 75 µl 
10 x Buffer  5. 00  µl    
MgCl2   3. 00  µl  (final concentration 1, 5 mM) 
dNTPs   4. 00 µl  (final concentration 200 µM) 
Rapid Load  3. 00 µl    
Taq Polymerase   0. 25 µl  (1, 25 Units) 
Primer    0. 50 µl  (final concentration 1 µM) 
DNA     1. 00 µl 
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PCR Programm: 
 
95 °C 10 min 
95 °C   1 min 
58 °C   1 min    
72 °C 80 sec 
72 °C 10 min 
  4 °C forever 
 
 
 
The used primers include overhangs for restriction sites of the overexpression vector 
pIRES2-EGFP and were designed by OligoPerfectDesigner Tm (Invitrogen) and 
purchased from Invitrogen, www.invitrogen.com. 
 
Gel electrophoresis was used to control the amplified vector insert on a 1 % TAE-
agarosegel supplemented with 0.1 % ethidium bromide, running at 100 V for 20 to 30 
min. For determination of the lengths of the DNA fragments, molecular weight markers 
(1 kb DNA-ladder, cat. no. N3232S and 100 bp DNA-ladder, cat. no. N3231S, both 
New England Bio Labs Inc., MA) were used (Fig. 8). After examination of the bands of 
interest by an UV transilluminator, the bands were cut out and the DNA was isolated by 
gel extraction. 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
Figure 8. Molecular weight markers. 1 kb and 100 bp molecular weight markers were 
used to determine the length of the DNA fragments by gel electrophoresis. 
 
 
40 cycles 
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Gel extraction was done with QIAquickTM Gel Extraction Kit (QIAGEN, PCR 
Purification Kit, cat. no. 28104) according to the protocol. Therefore, 3 volumes of 
Buffer QC (gel dissolving buffer) were added to the weighted cut out gel piece and 
incubated at 50 °C until the gel was completely dissolved. Afterwards the mixture was 
added on the QIAquick column, washed with buffer PE and eluted with 30 µl DNase 
free water. 
 
For overexpression of the gene of interest, the vector pIRES2-EGFP (cat. no. 6029-1, 
Clontech Laboratories Inc., CA) was used (Fig.9). It contained an internal ribosome 
binding site (IRES) of the encephalomyocarditis virus (ECMV) between a multiple 
cloning site and the enhanced green fluorescent protein coding sequence. The cds of 
interest was cloned into the multiple cloning site. Thereby the candidate gene and the 
fluorescent protein were translated from one single bicistronic mRNA. This permitted 
an efficient selection of transiently transfected mammalian cells expressing the EGFP as 
well as the protein of interest simultaneously. Thus the rates of transcription and 
translation of the EGFP and the overexpressed protein were equal. Differences occurred 
only due to different stability of the expressed proteins. EGFP is a red shift variant of 
wild type GFP (a protein found in the jellyfish Aequorea victoria) that has been 
optimized for brighter fluorescence and stronger expression in mammalian cell lines. 
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Figure 9. pIRES2-EGFP expression vector.pIRES2-EGFP was used as expression 
vector for exogenous overexpression of the candidate gene. 
 
 
Double digestion with appropriate restriction endonucleases (EcoRI, Cat.No. R0101S, 
SacII Cat. No. R0157S, BamHI, Cat.No. R0136S, New England Bio Labs Inc.) was 
used to generate sticky ends of the isolated gene fragments as well as of the expression 
vector. Adequate buffers (NEBuffer 4, Cat.No. B7004S, NEBuffer 3, Cat.No. B7003S, 
New England Bio Labs Inc.) were added and the reaction was carried out at 37°C or 2 
to 20 hours.  
 
DNA   5.0 µl 
10 x Buffer  2. 0 µl 
100 x BSA  0. 2 µl 
Restriction enzyme 1. 0 µl each (20 units / µl)  
H2O   10. 8 µl 
 
 
Before ligation, the overexpression vector was treated with 1µl CIP (calf intestinal 
alkaline phosphatase) for 1 h at 37 °C. CIP catalyzes the removal of 5´ phosphate 
groups from DNA, and since fragments without 5´phosphat groups cannot self-ligate, 
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the amount of properly ligated products rises whereas vector background of improperly 
self-ligated constructs is reduced. 
 
For ligation of the gene of interest into the overexpression vector pIRES2-EGFP, T4 
DNA Ligase (Invitrogen, cat. no 15224017) as well as ligation buffer (5x T4 DNA 
Ligase Buffer, Invitrogen, cat. no. 46300-018) were used. The ligation was carried out 
for 1 h at room temperature according to the following reaction mix: 
 
 
DNA insert  9 µl 
5 x Ligation Buffer 3 µl 
T4 DNA Ligase 1 µl  1 unit/µl 
Vector   1 µl 
H20   1 µl 
 
 
For transformation into ONE shot MAX Efficiency DH5αTM –T1R chemical 
competent cells (Invitrogen, cat. no. K4520-01) the cells (50 µl aliquot for each 
reaction) were thawed on ice and 5 µl of the ligation mix was pipetted directly into the 
competent cells, gently mixed by tapping and incubated on ice for 30 min, followed by 
heat shock at 42°C for 30 seconds. 
Afterwards, 250 µl SOC medium (prewarmed to 37°C) were added and the mixture 
incubated for 60 min at 250 rpm and 37°C. The transformed cells were plated onto LB 
medium plates supplemented with kanamycin for selection of the transformed 
DH5αTM, and incubated overnight at 37 °C.  
 
If direct ligation into pIRES2-EGFP was not successful, subcloning was done using 
TOPO TA Cloning ®Kit (Invitrogen, cat. no. K4520-01). 2 µl of the PCR product were 
directly ligated into 1 µl of TOPO® Vector and incubated for 10 to 30 minutes. 
 
Glycerol stocks of positive transformed DH5αTM , carrying pIRES2-EGFP containing 
the gene of interest, were made by adding 300 µl of 87% glycerol to 700 µl bacterial 
suspensions (positive cultures) and stored at -80°C.  
 
Capillary sequencing was done to verify the correct sequence of the cloned gene. 
Therefore, plasmid DNA was purified using the QIAprep Spin Miniprep Kit (QIAGEN, 
Cat. No. 27104) according to protocol. Sequencing was done with an ABI Prism 377 
sequencing detection system (Applied Biosystems, CA.). First, cycle sequencing 
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reactions were carried out to generate ddNTP-labelled DNA fragments; which then 
could be detected by the ABI Prism. 
 
 
Water (HPLC-grade)     5 µl 
Big Dye™ Reaction Mix (Applied Biosystems) 2 µl 
Sequencing primer (Invitrogen)   1 µl   
DNA       1 µl  
      
 
 
Cycle sequencing reaction program: 
 
96 °C  1 min. 
96 °C 12 sec.    
56 °C  7  sec. 
60 °C  2 min. 
  4 °C forever 
 
 
The labelled fragments were then isoloated from remaining ddNTPs using DyeEX 2.0 
Spin Kit (QIAGEN, cat. no. 63204) according to protocol. Finally the samples were 
prepared for sequencing by adding 20 μl formamide.  
 
Plasmid midipreparation results in DNA amounts up to 100 µg and was used to obtain 
endotoxin free DNA for subsequent transfection steps. Therefore 50 ml of LB medium 
supplemented with 50 µl kanamycin (25 µl / µg) were inoculated with 5 µl of sequence 
verified bacterial stock. Before harvesting the cells were incubated on a shaker (250 
rpm / 37°C) for 20 hours. Then the cell suspension was centrifuged (6000 x g / 4°C) and 
further handled according to protocol. Finally the endotoxin free DNA was dissolved in 
100 µl DNAse free water. 
 
DNA concentration was determined by measurement of the absorbance of the DNA 
sample at 260 nm using a U-2000 Spectrophotometer (Hitachi). Knowledge of the exact 
DNA concentration is relevant for subsequent experiments, since plasmid amount has to 
be adjusted to applied quantity of lipofectamin, a reagent essential for transfection. For 
the measurement 3 µ of the DNA sample were diluted 1:200 in 600 µl of DNAse free 
water and DNA concentration was obtained by following formula  
 
 
 
 
29 cycles 
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c [μg/ml] = OD260 x D x F    
c  ...concentration of initial  sample 
OD260 ...absorption at 260 nm 
D  ...dilution factor 
F  ...empirical factor (50 for dsDNA ) 
 
 
For RNA isolation cells were harvested and centrifuged (300 x g for 2 min). Afterwards 
cells were instantly resuspended in lysis buffer supplemented with 1 % ß-
mercaptoethanol. For homogenizing of the cell sample a QIAshredder® (QIAGEN) was 
used. Up to 700 μl of lysate was loaded on a QIAshredder spin column that was placed 
in a 2 ml collection tube, and centrifuged at maximum speed for 2 minutes. RNA 
Isolation of the homogenized lysate was carried out using Rneasy® Mini Kit 
(QIAGEN). The sample was mixed with one volume of 80 % RNAse-free ethanol an 
applied on an RNeasy column and centrifuged for 2 min at 13.000 x g. After a 
subsequent washing step the RNA was submitted to an on-column DNase digestion 
with an RNase-free DNase set (QIAGEN cat. no. 79254) to remove genomic DNA that 
could interfere with following real time PCR experiments. After further washing steps 
isolated RNA was eluted with 30 µl of RNAse-free water. 
 
For further Real Time PCR Experiments, the previous isolated RNA was transcribed 
into cDNA. Therefore 1 μg of isolated RNA was stocked up with DEPC-water to a 
volume of 10.5 μl, 0.5 μl of random hexamer primer as well as 1 μl 10 mM dNTPs were 
added and incubated for 5 min at 65°C. 4 μl single strand buffer, 2 μl 0.1 M DTT and 1 
μl RNAse were added whilst the sample was put on ice. After an incubation step of 2 
minutes at 25° C 1 μl Super Script II was added and the reverse transcription program 
using a thermal cycler was carried out as follows: 
 
 
25 °C 10 min. 
42 °C 50 min.    
70 °C 15 min. 
 
 
 
The generated cDNA samples were stored at –20° C for further use in High Throughput 
RT PCR. 
 
Since integrity of the target sequence is one of the key factors influencing the sensitivity 
of PCR experiments, a quality control of the transcribed cDNA was performed. The 
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method of choice was a multiplex PCR assay, which permits a valuation of the extent of 
RNA degradation due to the simultaneous amplification of control genes that are 
expressed at different levels. The transcripts were derived from four different 
housekeeping genes, generating four bands of different size, (Bcr, Abl, β2-MG and 
Pbgd), ranging from 128 bp to 377 bp. In high quality samples all four bands were 
visible whereas decline of quality due to degradation of the primary RNA samples or 
unsuccessfully reverse transcription decreasingly transcripts were amplified (Watzinger 
and Lion, 1998). 
 
 
High throughput real time PCR was carried out using TaqMan Low Density Custom 
Arrays (Applied Biosystems) that enables to perform 384 real time PCR reactions 
simultaneous, with both primers and probes already spotted on the plates. The arrays 
were designed using the 64 well formats that enable to apply 64 different pre-made 
assays on a 384-well plate thereby forming two series of triplicates. The assays were 
selected from a set of pre-made assays available on www.appliedbiosystems.com. When 
for one target gene multiple assays were available, the assay located nearest to the 5´end 
of the target was chosen. This permits successful amplification of cDNA even in case of 
incomplete reverse transcription of mRNA. 
 
To start the real time experiments the cDNA samples were diluted to a final volume of 
430 µl, mixed with 430 µl of TaqMan PCR Mastermix and 100 µl were applied directly 
into the loading ports of the TaqMan plates, resulting in four ports per cDNA sample 
and Low Density custom arrays. Centrifugation for two minutes at 330 g ensures an 
equal distribution of the applied mix into the designed wells and sealing of the plates 
inhibits diffusion between the reaction wells and prevents forming of bubbles. The 
following Real time PCR was carried out using a ABI Prism 7700 sequence detection 
system and the obtained data analyzed using the SDS 2.2 software. It was necessary to 
adjust threshold as baselines manually before the data were exported and further 
analyzed using Windows Excel program.   
Analyzing was done using the ΔΔCt method, where the change of transcription of the 
samples is compared to a reference group of housekeeping genes (Schmittgen and 
Livak, 2008 ).Since two arrays (DMA1 and DMA2) were used for the measurement of 
one sample, differences had to be corrected. Therefore Ct values of the sample were 
normalized to Ct values of the housekeeping gene GAPDH, which was then normalized 
 - 42 -
to the average Ct values acquired from Nars and Tardbp, two further housekeeping 
genes localized on DMA2. For the final results the difference between a calibrator 
(cDNA from cells transfected with empty pIRES2-EGFP) and the actual sample (cDNA 
from cells transfected with pIRES2-EGFP overexpressing a target gene) was built.  
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4.3. Cell Culture 
 
Human immortalized umbilical vein endothelial cells (iHUVECS), an hTERT 
immortalized endothelial cell line were used as a model system of diabetic 
microangiopathy in vitro (Bian et al., 2005).  
iHUVECS were grown in RPMI 1640 medium (GIBCO, Cat.No. 51800-035), 
supplemented with 10 % FBS (GIBCO, Cat.No. 10108-157) and 1 % 
penicilline/streptomycine (GIBCO, Cat.No.15140-122). The cultivation of these cells 
was done in an incubator supplied with 5 % CO2 and 90 % relative humidity at 37°C. 
The cells were passaged at 90 to 95 % confluence. Old, exhausted medium was 
removed, the cells shortly washed with 1 x PBS in order to remove serum residues that 
would inhibit following trypsine reaction. 1.5 ml 1 x trypsine/EDTA (GIBCO) was 
added and incubated for 2 – 3 minutes at 37 C°. Afterwards the reaction was stopped by 
adding complete medium. Centrifugation and suspension took place before the cells 
were distributed to new culture flasks (75 cm2) containing 14 ml complete medium. 
 
For long time storage cells were frozen in liquid nitrogen. Therefore iHUVECs were 
grown up to 90 % confluence before trypsine was added and the cells were harvested. 
After centrifugation the pellet was resuspended with a mixture of 1800 μl FBS and 200 
μl DMSO (99.5 %), distributed into two 1.5 ml tubes and stored at -80 °C for 2 to 3 
days. Afterwards the cells were put into liquid nitrogen for long time storage. 
For thawing of nitrogen frozen iHUVECs the cells were put into a water bath at 37 °C 
until they get a crushed-ice like consistence. Then 7 ml of complete medium were 
added, cells were resuspended and centrifuged and finally distributed in appropriate cell 
culture flasks. For complete removal of DMSO it was necessary to change the medium 
the next day. 
 
 
4.3.1. Immunofluorescence staining 
 
For immunofluorescence staining iHuvecs were seeded on chamber slides (40,000 cells 
/ 0,7cm2) and treated with 25 mM D-glucose to stimulate diabetic conditions. 25 mM 
L-glucose was added as osmotic control since this sugar can not be metabolized in the 
cell. After 72 h of glucose treatment at which D- and L-glucose (on the control slides) 
were added every 12th hour the cells were washed with PBS and fixed in 4% 
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paraformaldehyde (100 µl/cm2) for 10 minutes. Afterwards the cells were washed with 
PBS and treated with 0.1 % Triton X -100 (100 µl /cm2) dissolved in PBS in order to 
solubilize the plasma membrane. After washing with PBS, foetal calf serum (1:100 in 
PBS) was added to the cells for 30 minutes to block unspecific binding sites. 
Cells were washed again with PBS prior of incubation with 30 µl of the primary 
antibody (rabbit anti-RPL3 polyclonal antibody, 11005-1-AP, ProteinTech Group, Inc., 
1 µg/ ml) for 45 minutes. After subsequent washing steps with PBS the secondary 
antibody (Alexa Fluor® 594 goat anti rabbit IgG (H+L), 2 µg/ ml, A-21044, Molecular 
Probes) was applied for 45 min, cells were washed again with PBS and DAPI (10 
mg/ml) was added for 50 seconds. Finally, cells were washed again and covered with 
GelTol Mounting Medium (Thermo Electron Corporation, Waltham, MA) for analysing 
with fluorescence microscopy (Axiophot, Zeiss). 
 
 
4.3.2. Flow cytometry 
 
Flow cytometry was used as method of choice to select successful transfected 
iHUVECs due to the fluorescence ability of the EGFP protein. Therefore cells were 
harvesting 48 h after transfection by trypsinization, followed by centrifugation for 4 min 
at 1800 rpm. The cell pellet was then resuspended in 1 ml of complete medium and 
finally 1 μg/ml of 7-amino-actinomycin D (7-AAD, Fluka, Buchs SG, Switzerland, cat. 
no. 06648) was added.  
Flow cytometric cell sorting was carried out by the Division of 
Rheumatology/Department of Internal Medicine III in cooperation with the Core Unit 
Cell Sorting, both from the Medical University of Vienna. For sorting a BD 
FACSAria™ flow cytometer was used and EGFP emission was detected via FL1 
channel using a bandpass filter at 530±15nm. Sort criteria combined a generously wide 
scatterlight region excluding small particles (cell fragments and debris) with positivity 
for EGFP as well as negativity for 7-AAD. Furthermore, transfection efficiencies and 
EGFP half-life were determined using a BD FACSCalibur™ flow cytometer. The sorted 
EGFP-positive, 7-AAD negative cells were lysed in 350μl of RLT buffer supplemented 
with 1% β-mercaptoethanol and stored at -80°C until RNA isolation was executed. For 
isolation of sufficient RNA, the sorting had to yield at least 300,000 EGFP-positive 
cells. 
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4.3.3. Transfection   
 
Since cellular membranes create barriers for large and highly charged DNA molecules 
to enter cellular compartments, several techniques have been developed to facilitate 
cellular transfection. These methods include calcium phosphate precipitation, 
electroporation, DNA-DEAE complexes, microinjection, virus-mediated transfection, 
introduction of DNA via particle bombardment and lipid mediated transfection. The 
method of choice was liposome mediated transfection, using Lipofectamin2000, a 
cationic lipid carrier that complexes with nucleotides and mediates transfection of 
iHUVECs with plasmid DNA (Tanner et al., 1997; Kaiser and Toborek, 2001).  
For transfection the cells were cultured in a 75 cm2 flask and 30 µg of DNA, 
resuspended in 1875 µl Opti-MEM®, were mixed with 37.5 µl of lipofectamin2000, 
resuspended in 1875 µl Opti-MEM®, and incubated for 20 to 30 minutes. IHUVECs 
that were grown to confluence of 90 to 95 % were washed with Opti-MEM® before the 
transfection mix was added. After incubation of 2 hours the transfection mix was 
removed, the cells were washed and complete medium was added before incubation for 
40 to 45 hours was accomplished (5 % CO2, 90 % relative humidity, 37 °C). 
Afterwards tryptionized cells as well as removed medium were centrifuged at 1800 rpm, 
pellets pooled and prepared for flow cytometric cell sorting.  
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4.4. Biochemistry 
 
4.4.1. Western blotting 
 
Western blotting was used to verify interactions given by network algorithm. Therefore 
iHUVECs were grown up to 90 % confluence and transfected with pIRES2-EGFP, 
containing genes coding for proteins of interest. After 40 h of transfection, cells were 
harvested by trypsin addition and centrifugation at 1800 rpm. Afterwards the cell 
sample was solubilized in laemmli buffer supplemented with 0,02 % DTT, heated up to 
96 ° C for 3 minutes and centrifuged (10.000 x g, 5 minutes). For measurement of the 
protein concentration of the samples, a protein assay in laemmli buffer was done 
(Karlsson et al., 1994). 
Therefore the solubilized cell sample was diluted in laemmli buffer to a final 
concentration of less than 0, 3 mg/ml, and 150 µl were applied to a microtiter plate. 
Finally 100 µl of TCA were added, resulting in protein precipitation, illustrated in a 
yellowish colour of the sample. After a short incubation time of 10 to 30 minutes the 
turbidity at 570 nm was measured using a microplate reader. Absolute protein 
concentrations were determined with a BSA standard curve (measured concentrations 
starting at 10 up to 500 µg / ml).  
Resolving – and stacking gel (12 % SDS-Acrylamid) were prepared and loaded with 20 
µg of solubilized and diluted protein samples. To verify transfer efficiency and for 
approximating the molecular weight of the blotted proteins, a prestained protein ladder 
(Cat. No. #SM0671, Fermentas Life Science), consisting of highly purified coloured 
proteins, ranging from 10 kDa to 170 kDa was used. 
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Figure 10. Protein ladder for western blotting. Ladder proteins are covalently 
coupled with a blue dye, except for two reference bands, which are prestained with 
green (10 kDa) and orange (72 kDa) 
 
 
Electrophoreses (100 V, 90 minutes) and subsequently blotting onto a nitrocellulose  
membrane (17 V, overnight) made the proteins accessible to antibody detection and was 
performed  prior to Ponceau S staining, that visualized transferred and separated 
proteins. Since nitrocellulose membrane was chosen due to its protein binding abilities, 
interactions between the membrane and the used antibody for protein detection had to 
be prevented. Consequently the membrane was washed and destained with TBS-T, 
followed by blocking for at least 20 minutes in 25 ml of 5 % non-fat dry milk in TBS-T 
to saturate membrane’s binding sites, thus reducing background noise. After further 
washing steps the blotted membrane was incubated with a corresponding antibody 
against the protein of interest. The used primary antibody was diluted to the appropriate 
ratio in 4 ml 10 % non-fat dry milk in TBS-T and applied overnight at 4 °C. After 
rinsing the membrane (3 x 15 minutes) with TBS-T, incubation with the secondary 
antibody (HRP-antibody, anti-mouse or anti-rabbit, 1:4.000) was performed for one 
hour. After washing steps (3 x 15 minutes) the membrane was incubated with ECL 
plus™ Western Blotting Detection Reagent (Amersham Biosciences) for further 
detection and analyses using a Lumi-Imager F1™ (Roche Diagnostics).  
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4.4.2. Immunohistochemical staining  
 
Immunohistochemical staining was carried out on paraffin sections of human diabetic 
tissue, using the Avidin/Biotin Complex method, where a biotinylated and covalently 
HRP (horseradish peroxidase) conjungated secondary antbody is used, which binds to 
this avidin/biotin complex. The enzyme catalyses a chromogenic reaction, in which 
diaminobenzidine is converted into a brownish, insoluble precipitate. Counterstaining 
with haematoxilin colours the nuclei blue to envision the structures of the sections. The 
slides were prewarmed at 55°C for 30 minutes before starting following rehydration 
steps: 
 
Xylene 1  10 min 
Xylene 2  10 min 
Isopropanol 1  5 min 
Isopropanol 2   5 min 
96 % Ethanol  2 min 
80 % Ethanol  2 min 
70 % Ethanol  2 min 
60 % Ethanol  2 min 
H2Odd   5 min 
 
Afterwards the slides were incubated in citrate working solution at 100 °C for 20 
minutes, followed by incubation in destilled water for 5 minutes and in 2 % H2O2 for 15 
to 30 minutes. After washing steps in PBS the slides were blocked in 20 % BSA/PBS 
for 30 minutes before the first antibody was applied for 60 minutes. After subsequent 
washing steps in PBS, incubation for 30 minutes with the secondary, biotinylated 
antibody was carried out. After washing steps, the sections were incubated with 
Vectastain Elite ABC reagent for 30 minutes. In the next steps, DAB substrate solution 
was added for 2 to 10 minutes. For counterstaining with haematoxilin, the sections were 
again washed in destilled water for 5 minutes and stained with haematoxilin for 1 
minute. The slides were washed with water for 10 minutes, dehydrated in 60% -, 70 % -
, 80 % -. 96 % ethanol for 2 minutes each and in isopropanol and xylene for 5 minutes 
each. Finally the sections were embeded using Entellan® (Merck, Art. Nr. 1.07960). 
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5. Results 
 
5.1 Gene selection 
 
 
Network construction can be achieved by reverse engineering, a process of discovering 
the principles of a whole system by analysing its structure, function and operation. 
Perturbation experiments are carried out to calculate fold-changes in transcription level 
using TaqMan measurements. Subsequently, correlation coefficients can be determined, 
which describe the interactions between genes and so providing the basis for network 
architecture. Therefore, when starting practical work for this thesis, our first aim was to 
achieve fold-change data to start network calculation, assigning gene selection a crucial 
step in our work. As, however, technology restricted the number of genes, we had to 
select the genes contributing to the design of the low-density array following three 
strategies:  
First, primary blood endothelial cells were isolated from skin samples of five diabetic 
and eight non-diabetic patients and compared due to their expression profiles by DNA 
chip experiments (N. Wick, personal communication). This strategy resulted in 559 
genes (“ex vivo set”), showing differential regulation according to T-test and relative 
variance method (RVM). Out of this gene set two subsets (total of 74 genes, Appendix 
2) were determined. Subset 1 passed conventional criteria like signal intensity or 
associated with parameters of clinical relevance like basal membrane thickness or serum 
creatinine, as well as identical chromosomal location of the chosen genes. Subset 2 was 
selected out of the 559 by means of a minimum spanning tree (a subgraph of a 
connected, undirected graph that connects all vertices and has the least of all weights). 
This method allowed a gene ranking due to their connectivity and betweeness. Further 
selection criteria were achieved through tertiary data analysis using STRING and iHOP 
databases to investigate known protein interactions. For the second gene set (“in vitro 
gene set”) cultured immortalized blood vascular endothelial cells (iBECs) were treated 
with D- or L-glucose to stimulate diabetic conditions and again subjected to chip 
experiment. Out of 1684 genes showing differential regulation according to T-test and 
RVM, 23 genes overlapped with the ex vitro set, and finally five genes were selected for 
the design of the array, since they were similar regulated in ex vivo as well as in vitro. 
The last gene set was achieved by carefully reviewing literature for genes relevant to 
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diabetes and diabetic microangiopathy and resulted in the “in libro set” that comprised 
164 genes. Out of this literature search, 58 genes were included, completing the 125 
genes that define the custom low density microarray (Fig.11). Gapdh was spotted on 
DMA1 and DMA2 both to normalize these plates, which then were normalized to the 
average Ct values acquired from Nars and Tardbp, two further housekeeping genes 
localized on DMA2.  
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Figure 11. Design of the Low Density Array LDA. Genes that comprise the array 
were selected out of three different gene sets (ex vivo, in vitro, in libro gene sets) due to 
the described criteria. The array contained of two micro-fluidic cards, DMA1 (A) and 
DMA2 (B). On each of these cards two series of 64 different pre made assays were 
applied in triplicates, resulting in a total of 128 simultaneous quantitative real time PCR 
reactions.  
array I 
array II 
array I 
array II 
array I 
array II 
array I 
array II 
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After having finished the design of the LDA, the candidates for the cloning and 
subsequent transient expression process were selected (Krachler A., 2006). Note that 
these genes would finally be transiently overexpressed one at a time and their effect on 
transcription of all genes represented on LDA measured, including that of itself. 
However, due to cloning restrictions (i.e. fragments were too short or too long for 
cloning, cds was not available in expression vector or cloning process was not 
successful due to unknown reasons) expression data could not be generated from all of 
the 125 genes. To compensate for this, candidate gene selection was not limited to that 
present on the LDA but extended by educational decisions to additional genes derived 
from the ex vivo set.  
From the latter, we specifically intended to achieve a better insight into fundamental 
cellular processes like translation in the context of diabetic microangiopathy. We felt 
that using the LDA as a platform for constructing a network we could also obtain 
information about the position of selected candidate RNA’s in a diabetic network.  
Therefore, we screened the possible candidates from the ex vivo gene set for translation- 
associated genes, and identified the five ribosomal proteins RPL13, RPL23a, RPL3, 
RPLP0 and RPS2. After careful review of literature reviewing we selected Rpl3 over 
the other four genes, since Rpl3 met our demands of a bona fide critical component of 
the translation, specifically contributing to ribosome stability and involvement in the 
mot important process of peptide bond formation (Meskauskas et al., 2005).  
After this semi-automated process of gene selection these were subjected to cloning 
process as described in material and methods and finally contributed to High 
Throughput RT PCR experiments. Representative for all selected genes, Figure 12 
demonstrates distinct cloning steps like PCR amplification, subcloning into TOPO 
vector and cloning into pIRES2-EGFP, based on the results of Rpl3. Additionally, the 
designed primers, containing annealed extensions, are also illustrated. Successful 
experiments were detected by gel electrophoresis, resulting in bands according to Rpl3 
at 1211 kb. 
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Figure 12. Overview of the cloning process of Rpl3. Distinct cloning steps like PCR 
amplification (A), subcloning into TOPO vector (B), and ligation into the expression 
vector pIRES2-EGFP (C) are illustrated. Primers were designed as illustrated (D). Gel 
electrophoresis resulted in bands according to Rpl3 at 1211kb, to TOPO vector at 3.9 kb 
and to pIRES2-EGFP at 5.3 kb.   
 
 
 
 
 
 
 
 
 
C
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5.2. Endothelial RPL3 under diabetic conditions in situ 
 
In order to assure that our selection was of clinical diagnostic significance, we assessed 
its presence in the sections of the very same diabetic patients that had been the original 
source for ex vivo gene expression analysis. Therefore, skin samples of diabetic and 
non-diabetic patients were tested for RPL3 protein distribution and semi-quantitation 
using imunohistochemistry was done (Fig. 13). In both settings, RPL3 was detected in 
the endothelium of dermal blood capillaries. The reactivity was cytoplasmic and present 
in all blood vascular endothelial cells. Critically, the staining intensity was different in 
capillaries of non-diabetic compared to diabetic patients. While there was only weak 
positivity under normal conditions, staining intensity of diabetic samples was very 
strong. Occasionally a granular cytoplasmic signal could be observed in diabetic vessels 
(not shown). These data confirmed the gene expression experiment from ex vivo BECs 
and motivated us to further investigate Rpl3 as a –at least on histopathological level- 
clinically trustful candidate protein in diabetic microangiopathy. 
 
  
 
Figure 13. Immunohistochemical staining of RPL3 in non-diabetic and diabetic 
tissue. Skin samples from non-diabetic (A) and diabetic (B) patients were compared for 
RPL3 protein reactivity in the endothelial layer of dermal capillaries (arrows). Diabetic 
samples revealed a stronger reactivity. Magn.: 200x, epidermal reactivity in A is 
background signal. 
 B A 
 
 - 55 -
 
5.3. Endothelial RPL3 under diabetic conditions in vitro  
 
5.3.1. Endogenous RPL3 protein 
 
Since in vivo experiments demonstrated no convincing insight regarding the effects of 
diabetic conditions on RPL3 protein expression, in vitro analyses were performed. We 
decided to characterize in more detail this protein morphologically, using 
immunofluorescence analysis. In a first setup the effect of diabetic conditions on 
endogenous RPL3 was examined. Therefore, iHUVECs, immortalized cells mimicking 
the human endothelium, were treated with D-glucose. Osmotic control was achieved by 
treatment of parallel samples with L-glucose, a sugar that cannot be metabolized inside 
the cells. After 48 hours of induced diabetic conditions the stained protein accumulated 
in selected cells, where it enriched around the nucleus. In L-glucose treated cells a 
similar pattern was seen, but RPL3 seemed to be restricted to a small region around the 
nucleus. After 72 hours of diabetic treatment RPL3 aggregated in the whole cells 
whereas the majority of the L-glucose treated cells showed fluorescence staining still in 
a defined area around the nucleus. Nevertheless, a small part of these control cells 
demonstrated an aggregation pattern of the RPL3 protein as seen in diabetic cells. Since 
RPL3 was over expressed under diabetic conditions in vivo (as demonstrated in pre-
existing data), this observation is a moderate suggestion for a increased RPL3 synthesis 
in vitro as well (Fig. 14). 
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Figure 14. Immunofluorescence staining of endogenous RPL3 in iHuvecs. Cells 
were treated with D- and L-glucose and tested with an antibody against RPL3. D-
glucose treatment for 48 hours displayed RPL3 enrichment around the nucleus and 
aggregated in the cytoplasm (A). Additional 24 h of diabetic conditions confirmed the 
previous detected aggregation (B), whereas control cells maintained a diffuse 
cytoplasmic distribution pattern (C).  
 
 
 
 
 
 
 
A B 
C 
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5.3.2. Exogenous RPL3 protein 
 
To ensure that all relevant effects regarding RPL3 under diabetic conditions were 
examined and to guarantee that important features were not ignored due to minimal 
concentration of the endogenous protein, the impact of enhanced glucose concentration 
on exogenous RPL3 was also investigated. After overexpression of protein and glucose 
treatment morphological changes were observed. Already after 48h of diabetic 
treatment we could observe an aggregation pattern of RPL3 as seen in endogenous cells 
just after 72h of glucose addition. Accumulation was observed in the whole cells and 
particularly in the areas around the nucleus. Furthermore, the most notable difference 
between exogenous and endogenous expression was an accumulation of RPL3 in some 
cells, thereby forming globular-shaped inclusions in the nuclei. These structures could 
only be detected after glucose treatment for at least 48 h hours, glucose treatment for 
additional 24 h showed no evident difference in the described aggregation pattern of 
RPL3. 
In contrast, iHUVECSs treated with L-glucose showed no comparable structures. RPL3 
accumulation starts circular from the nucleus, completing the cytoplasm of the whole 
cells, resulting in a diffuse cytoplasmatic aggregation pattern. There was no detectable 
difference of this pattern after 24 h, 48 h and 72 h of L-glucose treatment. However, in 
some cells RPL3 was restricted to a small circular region around the nucleus. 
Summarizing, the pattern of aggregation in control cells showed high similarity to 
endogenous RPL3 expression under L-glucose enrichment (Fig. 15).  
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Figure 15. Immunofluorescence staining of iHuvecs expressing exogenous RPL3 
after glucose treatment. Exogenous expressing iHUVECS were contributed to D-
glucose treatment and stained with antibody against RPL3. After 48 hours globular 
shaped inclusions were detected (A, B, C, D). Control cells (E, F) displayed no similar 
structures. 
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5.4. Position of RPL3 in the genetic network  
 
In order to identify yet unknown connections between candidate genes, the acquired 
fold-change data were used to gain additional information of the diverse expression 
patterns and their functional relations. 
 
The final network was created by determining the fold change of all transiently 
expressed candidate genes and their effect on the expression of the residual gene set of 
the LDA. Although Rpl3 itself was none of the genes comprising the low density array, 
it was still relevant to add its expression data to network calculation since as part of the 
ex vivo set, this protein displayed different expression patterns in diabetic and non 
diabetic primary blood endothelial cells, thereby allowing speculations about an 
important role of Rpl3 in the pathogenesis of diabetic microangiopathy.  
 
A special algorithm (Stokic et al., 2008) was applied to achieve on transcriptional level 
diverse profiles relative to the other 127 genes represented in the LDA. The global 
expression profile demonstrates the impact of a single candidate gene overexpression on 
the gene set of the LDA and the global correlation identifies similar expression patterns 
between these global expression profiles. The global expression profile of Rpl3 was 
determined, demonstrating the impact of its transient expression on the gene set of the 
LDA. Although most of the perturbation experiment showed no relevant effect with fold 
change values ranging between 0.1 and 13.0, we still could detect 13 genes with 
different regulation due to Rpl3 expression. The detected fold-changes ranged between 
4*10 -4 and 1.85*1016, with values less than -1 indicating downregulation and values 
greater than +1 upregulation (Fig. 16): 
Rpl3 overexpression revealed a negative regulation on four genes: Complement 
component 1, s subcomponent (C1s), glyceraldehyde 3-phosphate dehydrogenase 
(Gapdh), platelet-derived growth factor alpha polypeptide (Pdgfa) and 
phosphoglycerate dehydrogenase (Phgdh), displaying the following fold change values: 
1*10 -3 (C1s), 3.5*10-3 (Gapdh), 4*10 -4  (Pdgfa) and 2.9*10-2 (Phgdh). 
Next we examined enhancing effects of Rpl3 expression on the genes of the LDA set, 
thereby detecting five genes that were upregulated due to Rpl3 overexpression: 
Chemokine (CXC motif) ligand 12 (Cxcl12), human fibroblast growth factor 1 (Fgf1), 
Ras homolog gene family, member J protein (Rhoj), Rap2 interacting protein (Rpib9) 
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and thrombomodulin (Thbd). These genes revealed, in alphabetical order, correlation 
values of 1.85*1016, 22.74, 168.0, 169.0, 23.93. 
As already mentioned, transient RPL3 expression did not have any significant effect on 
the remaining genes of the LDA set, since their detected fold-change values were 
limited to the span between 0.1 and 13.0 and according to our definition, upregulating 
and downregulating effects ranged higher or respectively lower than these values.  
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Figure 16. Global Expression Profile of RPL3. C1s, Gapdh, Pdgfa and Phgda were 
downregulated due to transient RPL3 expression while Cxcl12, Fgf1, Rhoj, Rpib9 and 
Thbd revealed a positive regulation. The detected fold change values ranged between 
4*10 -4 for Pdgfa and 1.85*1016 for Cxcl12. The remaining genes of the LDA set did not 
respond to Rpl3 overexpression, their fold change values ranged between 0.1 and 13.0. 
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Next the global correlation profile was determined, identifying overexpressed genes 
with the same effect on the LDA gene set as exogenous Rpl3 (Table 1). Critically, Btf3 
showed a value of 0.84 relative to Rpl3, indicating a correlation of 84 %. This suggested 
a strong relationship between these two genes. The genes with correlation values next in 
size to Btf3 were cholesterol-lowering factor (Clf) with 33 % and Phgdh with 31 %.  
 
Table 1. The global correlation profil of RPL3.  
Perturbation Experiment Correlation in % Perturbation Experiment Correlation in %
AQP1 7 ICAM 10 
ATP6V0D1 30 IFITM 11 
BTF3 85 IMPA 18 
CALM2 16 KLF6 6 
CASP3 0 L-glucose treated iHUVECs 9 
CDYL12 11 NOS3 6 
CFH 18 PHGDH 31 
c-Jun 3 pIRES-EGFP empty 3 
CLF 33 pIRES-EGFP empty 12 
CSPG 5 pIRES-EGFP empty 29 
CXCL12 27 pIRES-EGFP empty 22 
CYR61 11 PKA 5 
D-glucose treated iHUVECs 27 PLD 10 
ET1 8 PRG 23 
FGF1 6 PRSS23 6 
FZD4 14 RAMP3 5 
GAPDH 9 RHOJ 26 
GCA 6 RPL3 100 
GDI2 6 Sample02 16 
GNAS 23 SMAD2 5 
GNAS2 7 SMAD3 7 
GTPBP4 29 TGFb1 5 
HOXA3 13 TGFb-R2 3 
HOXA3_new 13 TOR3A 26 
HOXA3-2nd run 9 UGDH 11 
 
The correlation value entitles the degree of similarity between the expression patterns of 
the candidate genes. 
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To verify the indicated correlation between Rpl3 and Btf3, we examined the expression 
profile of Btf3, thus identifying a relation between these two genes in the regulation of 
Cxcl12, Rpib9 and Gapdh (Figure 17). Cxcl12 and Rpib9 revealed positive regulation 
upon transient BTF3 expression, with detected fold-changes of 3.9*1017 and 5565.0, 
whereas Gapdh was downregulated at a value of 3.7*10-3. In contrast to these similar 
expression patterns of Rpl3 and Btf3, Pdgfa showed a different regulation, revealing 
enhancing effects due to Btf3 overexpression.  
 
Table 2. Global expression profils of BTF3 and RPL3.  
Detected gene Detected fold-change RPL3 Detected fold-change BTF3 
ANGPT2 - 2747.0 
C1S 1*10 -3 - 
CXCL12 1.85*1016 3.9*1017 
FGF1 22.74 - 
GAPDH 3.5*10 -3 3.7*10-3 
GCA - 1.8*10-2 
MMP9 - 11996 
PDGFA 4*10 -4 1740 
PHGDH 2.9*10-2 - 
RHOJ 169 - 
RPIB9 17.93 5565 
SOD1 - 444 
 
The global expression profiles of Rpl3 and Btf3 revealed the detected fold-change 
values of the two genes. Note that only values over 13.0 for upreglation and under 0.1 
for downregulation are listed. 
 
Furthermore, the global expression profile of Btf3 revealed four additional genes with 
notable regulation patterns, among which angiopoietin-2 (Angpt2), matrix 
metallopeptidase 9 (Mmp9) and superoxide dismutase 1 (Sod1) were upregulated, 
whereas grancalcin (Gca) showed downregulating effects due to transient Btf3 
expression.  
 
Finally, we examined the correlation pattern of Btf3, thus identifying similar expression 
patterns of the candidate genes on the LDA set. Again, a correlation value of 0.85 with 
Rpl3 was detected, thereby confirming our previous result. Taken together, this finding 
may suggest a strong “molecular” connection between the genes Rpl3 and Btf3. 
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Figure 17. Global Expression Profile of BTF3. Gapdh and Gca were downregulated 
due to transient Btf3 expression while Cxcl12, Pdgfa, Sod, Rpib9, Angpt2 and Mmp9 
revealed a positive regulation with detected fold change values ranging between 3.7*10 
-3 and 3.9*1017. The regulation patterns of Cxcl12, Gapdh and Rpib9 resemble the 
expression profile of Rpl3, whereas Pdgfa reveals different regulation.  
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5.5. Verification of RPL3 interactions in a genetic network 
 
The analysis of the expression patterns of Rpl3 and Btf3 revealed a similarity regarding 
their effects on the regulation of the LDA gene set. These results were confirmed by the 
high correlation values of 0.85, assuming a yet unknown connection between Rpl3 and 
Btf3. Nevertheless, it was essential to verify these indicated interactions by separate 
methods. Since we assumed that RPL3 and BTF3 act together on protein level, Western 
blotting was chosen for further investigation. Thus, iHUVECs expressing exogenous 
RPL3 and BTF3 were tested using antibodies specific for these proteins, and compared 
to cells transfected with empty pIRES2-EGFP expression vector. Besides, all three cell 
samples were also tested for CD31, a type I integral membrane glycoprotein, also 
known as platelet endothelial cell adhesion molecule 1 (PECAM1). Since CD31 is 
constitutively expressed on the surface of endothelial cells, it allows comparing of 
different cell samples due to their blotted protein concentration, thereby acting as 
marker protein for iHUVECs.  
The detection of BTF3 protein revealed expected results: Total BTF3 protein 
accumulated in cell samples that overexpressed BTF3 but was present at comparable 
and lower levels upon overexpression of RPL3 as well as control vector (data not 
shown).  
On the contrary, when identifying RPL3 in iHUVECs transiently expressing either 
RPL3 or BTF3, a high level of RPL3 was detected (Fig. 18). Specifically, both cell 
lysates displayed identical signal intensities, corresponding to RPL3’s predicted 
molecular weight of 44 kDa, thereby demonstrating a sound accumulation of RPL3 
protein in lysates of exogenous BTF3 expression. In control samples significantly less 
RPL3 protein was detected. The similar expression of the RPL3 protein both, in RPL3 
and BTF3 overexpressing iHUVECSs, confirmed our previous results of a tight 
connection between these two proteins.  
Summarizing, these findings allows the assumption of a unilateral pathway, in which 
BTF3 stimulates the expression of RPL3. 
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Figure 18. Western blot analyses of RPL3 and BTF3 overexpressing iHUVECs.  
RPL3 detection in iHUVECs expressing exogenous RPL3 and BTF3 results in equal 
signal intensities at 44 kDa, whereas control cells displayed a much weaker RPL3 
expression, indicating an unilateral pathway with BTF3 enhancing the expression of 
RPL3.  
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5.6. The position of BTF3 in the final gene network 
 
The transcriptional network of diabetic microangiopathy was achieved with fold-change 
data of perturbation experiments and displayed the regulatory interactions of the 
participating genes. As described, candidate genes were subjected to a multi-step 
process, involving cloning into the expression vector pIRES2-EGFP, transformation 
into iHUVECs, RNA isolation and reverse transcription into cDNA prior to quantitative 
real time PCR. Finally, Network identification was accomplished by multiple regression 
according to the following formula:  
 
A= ln (D+I) 
 
Since the influence matrix D displayed the effect of perturbation experiments on the 
expression of the remaining genes, the network was designed by adding the regulatory 
interactions found between the transient expressed candidate genes, thereby revealing 
different regulation patterns. Functional links were determined between each of the 
genes, thus illustrating enhancing and inhibiting effects. Due to these regulatory 
interactions it was possible to establish the position of each gene in a network relevant 
to diabetic microangiopathy.   
Since only genes with a correlation coefficient greater than the threshold were 
submitted to graph constructions, the definition of the applied threshold was significant 
for the calculation of the network and was set according to a previous carefully selected 
connectivity value. A threshold set too high results in small gene clusters and 
unconnected nodes, thereby concluding no functional connections of the involved 
genes. On the contrary, if threshold setting is too low, numerous false positive links are 
deduced from network topology. Based on this consideration we finally included only 
genes with correlation values above 1.334 for enhancing effects and below -1.130 for 
inhibiting effects.  
Due to this stringency, the final network displayed 37 genes that were assumed to be 
relevant in the pathogenesis and the progression of diabetic microangiopathy (Figure 
19). Out of these transiently expressed genes, caspase 3 (Casp3), calmodulin 2 (Calm2), 
Clf, Cxcl12, Gapdh and Prss23 were detected to be key players of diabetic vascular 
diseases, since they displayed a vast number of regulatory interactions or network links, 
thus being identified as hubs of the network.  
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Rpl3 was not relevant for network design, since the detected correlation values did not 
exceed the defined threshold. However, regulatory interactions from Btf3 to nine 
network participants were identified (Table 3).  
Btf3 displayed enhancing effects on Cxcl12, chondroitin sulfate proteoglycan 2 (Cspg2) 
and Rpib9, whereas Aqp1 (aquaporin 1), Calm2, Fgf1, complement factor H (Cfh) and 
phospholipase D (Pld) were downregulated upon exogenous Btf3 (Table 3). Contrary, 
transient expressed Casp3 revealed inhibitory effects, thereby downregulating the 
expression of Btf3. These detected functional links connected Btf3 directly to four out of 
seven identified hubs, thus implying a significant role of Btf3 in the network.  
 
Table 3. Detected interactions between BTF3 and the 36 remaining genes of the 
network.  
Effect of BTF3 to Strength of detected interaction 
AQP1 -3,65 
CALM2 -2,13 
FGF1 -1,97 
CFH -1,82 
PLD -1,75 
ICAM -1,74 
SMAD2 -1,56 
RPIB9 3,18 
CSPG2 3,31 
CXCL12 8,24 
Effect to BTF3 from Strength of detected interaction 
CASP3 -1,55 
 
Network interactions of Btf3 to and from the 36 remaining genes. Note that only effects 
above threshold were listed. 
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Figure 19. Final network of diabetic microangiopathy. The final network on diabetic 
microangiopathy displayed 37 genes, whereof Casp3, Calm2, Clf, Cxcl12, Gapdh, 
Rpib9 and Prss23 revealed a vast number of regulatory interactions. Btf3 connects to 
four of these network hubs, in both upregulating and downregulating way, indicating 
the important role of this protein in diabetic microangiopathy. Note that enhancing 
effects were illustrated in unbroken, inhibiting effects in dotted lines.  
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6. Discussion 
 
 
In this thesis we present the identification of a genetic network of human diabetic 
microangiopathy. Our ambition was to reveal definite target genes of this disease that 
prospectively could be subject to further investigation, thereby leading finally to drug 
development against this vascular disease. As described in this thesis, the target genes 
for the Low Density Array and for network construction respectively were selected out 
of three approaches. First, the ex vivo set was established from differential gene 
regulation in diabetic versus non-diabetic blood endothelial cells (BECs), whereas the in 
vitro set comprises immortalized BECs (iBECs) in cell culture mimicking diabetic 
condition by treatment with glucose. In the third approach an educated decision was 
performed by carefully reviewing literature on diabetic microangiopathy, resulting in 
the in libro set. 
In order to construct the genetic network on diabetic microangiopathy, the selected 
candidate genes were subjected to working steps, involving the cloning into the 
expression vector pIRES2-EGFP, the transfection of iHUVECs, subsequent RNA 
isolation of positively transfected cells, reverse transcription into cDNA and finally real 
time PCR.  
 
The whole process resulted in a network consisting of 37 genes, their positions which 
were described due the functional and regulatory relations and illustrated by the number 
of given links between the network participants. The genes Casp3, Calm2, Clf, Cxcl12, 
Gapdh, Rpib9 and Prss23 were found in more central positions with vast numbers of 
interactions, thereby considered to act as hubs or key players. Although a large pool of 
target genes was available, only 37 of the originally present candidates were 
successfully subjected to the transcriptional network. The main reasons for this 
limitation were found in the time consuming-multi step process of transient target gene 
expression. Nevertheless, the small number of genes building the network gives rise to 
discussions about its relevance. Critically, it stays disputable, if these identified hubs are 
truly relevant in terms of understanding the whole process that underlies diabetic 
microangiopathy. It is highly unlikely that all diabetic complications are based on the 
action of one single gene. Instead, network hubs should be seen as indicative, since also 
genes in peripheral positions could be important for the complete comprehension of the 
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numerous factors involved in the occurrence and pathology of the discussed disease. 
Additionally, the ultimate target genes and their interactions could still be undetected 
due to the small number of participants.  
Nevertheless, the network gives insight into the complex interactions of the disease in 
question and helps to identify possible key player of diabetic microvascular 
complications.  
The workflow comprised the cloning of candidates into the expression vector pIRES2-
EGFP, which permitted an efficient selection of transiently transfected cells expressing 
the enhanced green fluorescent protein EGFP as well as the protein of interest 
simultaneously. Unsuccessful ligation into pIRES2-EGFP in the first place required 
subcloning into the TOPO TA vector, thereby again prolonging the cloning process. 
The subsequent transfection step was accomplished in iHUVECs, an hTERT 
immortalized endothelial cell line. iBECS would be the first choice for an in vitro 
system mimicking diabetic microangiopathy, but were changed to iHUVECs due to low 
transfection rates. Former studies determined a total number of at least 250.000 positive 
transfected cells, since a smaller amount of iHUVECs resulted in fewer material for 
succeeding total RNA isolation, thereby affecting the quality of cDNA as well as the 
validity of subsequent real-time experiments (Krachler A., 2006). Although transfection 
efficiency of iHUVECs was much higher than of iBECs, successful transient gene 
expression often demanded repeated transfection and subsequent pooling of the GFP-
expressing cells to acquire the minimal number of at least 250.000 cells, thereby again 
prolonging the process of transient gene expression. Nevertheless, we successfully 
finished this workflow with 45 overexpressed candidates, but this number was further 
limited due to threshold, which was set according to in advanced selected connectivity 
value. If setting was too high, only small gene clusters without further interactions 
between the genes would result from network calculation. Otherwise, if the threshold 
was set too low, the network would in fact conclude all the 45 transiently expressed 
genes. However, numerous false links would be deduced, thereby leaving the 
significance of such networks sceptical. Based on these considerations, only genes with 
correlation values in the range of -1.130 to 1.334 were subjected to the network, thus 
resulting in the total of our 37 participants. 
 
As mentioned, the selected threshold criteria characterised network architecture by 
determining the number of participants. As a result, Rpl3 was one out of eight 
 - 72 -
transiently expressed genes that was finally not represented on the network. Despite this 
fact, it was nevertheless important to add its fold-change data to network calculation, 
since its algorithm revealed a high similarity of Rpl3 and Btf3 concerning the effect of 
their transient expression on the gene set of the low density array. The high correlation 
of 85% between Rpl3 and Btf3 indicated a connection between these two genes, thereby 
linking Rpl3 to the gene network. Btf3 itself exposed interactions to four of the seven 
identified hubs, thus being highly interconnected to the network. Out of these, Calm2 
was downregulated, whereas Cxcl12 and Rpib9 were upregulated as an effect of 
transient BTF3 expression.  
Calm2 is one out of three genes coding for calmodulin, a calcium binding protein that is 
involved in numerous cellular processes like synthesis and degradation of cyclic 
nucleotides, the regulation of different transport system, in phosphorylation and 
dephosphorylation processes of proteins (Benaim and Villalobo, 2002). 
The gene Cxcl12 encodes the Chemokine (C-X-C motif) ligand 12, also referred as 
stromal cell-derived factor 1 (SDF-1) or pre-B cell growth stimulating factor (PBSF). 
CXCL12 triggers its functions primarily by binding to two main receptors, CXCR4 and 
CXCR7. The CXCL12/CXCR4 axis plays an important role in embryogenesis by 
directing the migration of haematopoietic stem/progenitor cells from foetal liver to bone 
marrow and in the formation of large blood vessels. In the adult body, CXCL12/CXCR4 
binding is also involved in inflammatory processes and seems to be crucial for 
angiogenesis by recruiting endothelial progenitor cells from the bone marrow. 
Additionally, binding of CXCL12 to the CXCR7 receptor effects important processes as 
cell survival, cell adhesion and tumorgenesis (Kucia et al., 2003). 
The Rpib9 gene, also known as Rpip9 (Rap2 interacting protein) or Rundc3b (RUN 
domain containing 3B) codes for the Rap2-binding protein 9. Rpib9 is known to be 
activated in breast cancer and also correlates with metastatic lymph node invasion 
(Raquz et al., 2005). 
Finally, Btf3 itself revealed downregulating effect upon transient Casp3 expression, the 
gene coding for caspase 3. Caspases are proteins of the cysteine-aspartic acid protease 
family and are involved in apoptotic pathways (Nuñez et al., 1998). Casp3 is also 
associated with the apoptosis of the β islet in the pancreas, a process that is important 
for the development of type I diabetes (Liadis et al., 2005).  
 
 - 73 -
Although only Casp3 and Cxcl12 are known by former studies to be associated with 
diabetic microangiopathy, the genes Calm2 and Rpib9 are still relevant, since they are 
also targeted by a vast number of interactions and are highly connected to the other hubs 
as well as to more peripheral genes.  
 
Still, these given network links have to be verified. Assuming that RPL3 and BTF3 act 
together on a protein level, western blot analysis was used to proof these indicated 
interactions. Thus, iHUVECs that were transiently expressing RPL3 and BTF3 
respectively were compared to cells transfected with empty pIRES2-EGFP, resulting in 
enhanced RPL3 expression in both cell samples. In order to avoid that eventual side-
effect of the transfection process would distort western blot results or lead to false 
assumptions, control samples were transfected with empty pIRES2-EGFP. The 
immunoblotting result confirmed the indicated connection between both genes, thereby 
explaining the similarity of the effect of transiently expressed Rpl3 and Btf3 on the gene 
set of the LDA. Since only overexpressed BTF3 affected RPL3 expression and not vice 
versa, we assumed a unilateral pathway, in which BTF3 leads to an enhanced RPL3 
expression.  
 
Nevertheless, some technical problem had to be overcome in order to verify network 
links and to get reproducible results. A protein assay in Laemmli buffer (Karlsson et all, 
1994) was performed to gain equal concentration of the applied cell extracts. However, 
this method proved to be unsuitable for our cell lines by causing incomparable protein 
concentration and consequently leading to false results. Therefore, protein 
concentrations of the used cell samples were additionally determined by BSA standard 
curve, resulting in comparable amounts of the blotted samples and thus in convincing 
results.  
 
Additionally, the used iHUVECs were a poor model for capillary endothelial cells. 
Initially, iBECS were intended as model system, since they were a more suitable system 
to mimic diabetic caused vascular complications. However, former experiments 
revealed transfection rates only between 0.1 % and 0.3 %. Therefore, iBECS were 
rejected for iHUVECs, which allowed the use of Lipofectamine 2000, an effective 
transfection reagent, thus resulting in higher transfection efficiency (Krachler A, 2006).  
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Finally, transfection kinetics did also play an important role in getting reproducible 
network verifications. Former experiments (Krachler A, 2006) revealed a transfection 
curve peaking 22 hours after transfection, followed by a lower steady state level 
between 30 and 52 hours, in which stable expression of the candidate gene occurred. 
 
For network construction, 48 hours after transfection were chosen for RNA 
measurement, thereby assuring that next to early genes also the effects of late 
responding genes were considered. For immunoblotting experiments we observed next 
to the approved time point of 48 hours also 24 and 36 hours after transfection. 
Nevertheless, after optimizing the referred working steps, only cell samples harvested 
48 hours after transfection illustrated reproducible results, thereby verifying the 
assumed interaction between BTF3 and RPL3 and confirming the constructed network. 
Cell samples with time points of 24 and 36 hours did not reveal any interaction, giving 
way to the consideration that a threshold concentration of BTF3 protein was required to 
trigger RPL3 expression, or that the sensitivity of the technique did not expose this 
pathway.  
 
Critically, for biochemical analyses the cell samples were not cultivated in 
hyperglycaemic serum, thereby raising the questions, if a diabetic glucose level 
confirmed or rejected the previous results. Nevertheless, immunoblotting was our 
method of choice for the verification of the detected network links. Given the fact that 
Btf3 was part of the gene set comprising the Low Density Array, which was primary 
selected due to different regulation in diabetic compared to non-diabetic tissue, transient 
BTF3 expression in western blot analyses mimicked its enhanced expression as reported 
under diabetic conditions (N.Wick, personal communication). Finally, the enhanced 
RPL3 expression as illustrated in immunoblotting was based on transient expressed and 
thereby diabetic BTF3.  
 
In summary, our results illustrated the upregulation of both genes, Rpl3 and Btf3, under 
diabetic conditions. Given the fact that the designed network was based on regulatory 
interactions on the RNA level, further verifications of the observed network links would 
demand approaches on a protein level. These methods could include mass spectrometric 
screens, antibody arrays or even serological analyses.  
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Apart from its known function in ribosome assembly, recent findings indicated a more 
central role of RPL3 in translation by coordinating the functions of the sarcin/ricin loop 
(SRL) and the peptidyl transferase centre (PTC), thus taking part in translational 
elongation. Also BTF3 is known for acting in translation process in the proximity of the 
PTC by performing cotranslational targeting of polypeptides to the endoplasmic 
reticulum (ER). Given the fact that both proteins take part in translation associated 
processes, although fulfilling different functions, and are induced under diabetic 
conditions makes a common pathway in the presence of high glucose levels more likely. 
 
In addition, the upregulation of RPL3 is consistent with known observations of higher 
translation rates as a consequence of high glucose levels. This goes in line with our 
observation of immunofluorescence analyses that revealed bona fide RPL3 containing 
aggregates.  
Diabetic tissue analyses by immunohistochemistry confirmed the increase of RPL3 
protein. Still, these findings are not significant in clinical-diagnostic terms, since IHC is 
as localization tool the method of choice for qualitative and not quantitative statements. 
However, these results could be considered as semi-quantitative according to the 
prominent RPL3 protein staining demonstrated in the tissue sections of diabetic 
patients. Additionally, the granular reactivity corresponds to the ribosomal pattern as 
already illustrated in in vitro immunoflourescence analyses.  
Further confirmations of this enhanced RPL3 expression under the discussed conditions 
could include electron microscope analyses. Alternatively, subcellular fractionation 
resulting in high amounts of ribosome and upregulated RPL3 protein would allow a 
more direct verification of RPL3 on a protein level. Both techniques should be 
considered in follow up experiments.  
 
To summarize our work, in this thesis we presented a genetic network comprising 37 
genes. Within the network two new potential candidates relevant for diabetic micro- 
vascular complications, Btf3 and Rpl3 were identified. Although Rpl3 itself was not 
represented on the LDA and thus not first choice for transient gene expression, the 
decision for this gene turned out useful eventually, since the correlation of Rpl3 to  
Btf3 and thus to four of the seven identified hubs or key players of the constructed 
network also links translation and ribosome function to diabetic microangiopathy. Of 
course, inferrel of functional information from this thesis is limited. For such a 
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conclusion, another level of inhibitory experiments, e.g. RNA interference, would have 
been necessary. However, the central role of ribosomal proteins would have made any 
experimental readout a difficult task as the differentiation of diabetic and non-diabetic 
effects would have been difficult. Probably, the method of choice is analysis of 
appropriate animal models. In light of this prospect, we feel that our insight into 
translation as a basic target for diabetic effects in endothelial cells is a step forward in 
understanding its functional relevance in this disease. Thus, in a wide context, this study 
might provide targets for future drug therapy against the onset of diabetic 
microangiopathy.  
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8. Appendix 
 
Table 4. Networkinteractions  
 
Interaction 
from 
Interaction  
to 
Strenght of 
Interaction 
Interaction 
from 
Interaction  
to 
Strenght of 
Interaction 
AQP1 AQP1 2,722051 ATP6V0D1 CSPG 2,07361 
AQP1 ATP6V0D1 -0,007463 ATP6V0D1 CXCL12 5,265143 
AQP1 BTF3 0,134059 ATP6V0D1 CYR61 0,81192 
AQP1 CALM2 0,025582 ATP6V0D1 Endothelin 1 0,790161 
AQP1 CASP3 0,369031 ATP6V0D1 FGF1 -1,242175 
AQP1 CDYL12 0,031851 ATP6V0D1 FZD4 0,629283 
AQP1 CFH -0,30251 ATP6V0D1 GAPDH -3,279249 
AQP1 c-Jun 0,293258 ATP6V0D1 GCA -0,619129 
AQP1 CLF 0,283436 ATP6V0D1 GDI2 0,089239 
AQP1 CSPG 1,141788 ATP6V0D1 GNAS2 -0,414404 
AQP1 CXCL12 -0,548603 ATP6V0D1 GTPBP4 -0,100111 
AQP1 CYR61 0,270721 ATP6V0D1 HOXA3 0,122829 
AQP1 Endothelin1 0,16569 ATP6V0D1 ICAM 0,89925 
AQP1 FGF1 -0,505472 ATP6V0D1 KLF6 0,117326 
AQP1 FZD4 0,092528 ATP6V0D1 NOS3 0,893727 
AQP1 GAPDH 0,100185 ATP6V0D1 PHGDH -0,808789 
AQP1 GCA 0,081266 ATP6V0D1 PLD -1,496417 
AQP1 GDI2 -0,023122 ATP6V0D1 PRG -0,589468 
AQP1 GNAS2 -0,002362 ATP6V0D1 PRSS23 1,535841 
AQP1 GTPBP4 -0,011851 ATP6V0D1 RAMP3 -0,429829 
AQP1 HOXA3 0,068006 ATP6V0D1 RHOJ 0,806569 
AQP1 ICAM 0,301902 ATP6V0D1 RPIB9 -0,119441 
AQP1 KLF6 0,134175 ATP6V0D1 Smad2 -1,246196 
AQP1 NOS3 0,064439 ATP6V0D1 SMAD3 0,441503 
AQP1 PHGDH -0,053721 ATP6V0D1 TGFb1 0,164494 
AQP1 PLD -0,189371 ATP6V0D1 TGFb-R2 -0,273231 
AQP1 PRG 0,12705 ATP6V0D1 TOR3A -0,43736 
AQP1 PRSS23 0,147562 ATP6V0D1 UGDH 0,917983 
AQP1 RAMP3 -0,201398 BTF3 AQP1 -3,652131 
AQP1 RHOJ -0,000233 BTF3 ATP6V0D1 0,414528 
AQP1 RPIB9 0,159107 BTF3 BTF3 1,229077 
AQP1 SMAD2 0,219555 BTF3 CALM2 -2,130973 
AQP1 SMAD3 0,253928 BTF3 CASP3 -0,545044 
AQP1 TGFb1 -0,005141 BTF3 CDYL12 -0,301147 
AQP1 TGFb-R2 0,102489 BTF3 CFH -1,81942 
AQP1 TOR3A -0,075687 BTF3 c-Jun 0,704005 
AQP1 UGDH 0,19852 BTF3 CLF -0,933266 
ATP6V0D1 AQP1 -3,08974 BTF3 CSPG 3,306348 
ATP6V0D1 ATP6V0D1 2,325257 BTF3 CXCL12 8,242679 
ATP6V0D1 BTF3 -0,376401 BTF3 CYR61 1,073831 
ATP6V0D1 CALM2 -1,974402 BTF3 Endothelin1 0,813671 
ATP6V0D1 CASP3 -0,085988 BTF3 FGF1 -1,968983 
ATP6V0D1 CDYL12 -0,676129 BTF3 FZD4 0,657172 
ATP6V0D1 CFH -2,044165 BTF3 GAPDH -0,619802 
ATP6V0D1 c-Jun 0,988746 BTF3 GCA -0,479607 
ATP6V0D1 CLF -0,920006 BTF3 GDI2 0,280371 
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from 
Interaction 
to 
Strenght of 
Interaction 
Interaction 
from 
Interaction 
to 
Strenght of 
Interaction 
BTF3 GNAS2 -0,450612 CALM2 SMAD2 -1,782508
BTF3 GTPBP4 -0,144592 CALM2 SMAD3 0,970076
BTF3 HOXA3 -0,226815 CALM2 TGFb1 1,074866
BTF3 ICAM -1,74477 CALM2 TGFb-R2 0,365716
BTF3 KLF6 0,144336 CALM2 TOR3A -0,578279
BTF3 NOS3 0,909243 CALM2 UGDH 2,927373
BTF3 PHGDH -0,591673 CASP3 AQP1 -2,656819
BTF3 PLD -1,748211 CASP3 ATP6V0D1 1,140607
BTF3 PRG -0,863597 CASP3 BTF3 -1,546986
BTF3 PRSS23 1,095389 CASP3 CALM2 0,888856
BTF3 RAMP3 -0,603226 CASP3 CASP3 -3,999093
BTF3 RHOJ 0,665645 CASP3 CDYL12 -0,604778
BTF3 RPIB9 3,182712 CASP3 CFH 3,117886
BTF3 SMAD2 -1,555074 CASP3 c-Jun 0,185592
BTF3 SMAD3 -0,225375 CASP3 CLF 0,798349
BTF3 TGFb1 -0,478121 CASP3 CSPG 0,953982
BTF3 TGFb-R2 -0,707906 CASP3 CXCL12 3,062254
BTF3 TOR3A -0,146376 CASP3 CYR61 1,290601
BTF3 UGDH 0,904876 CASP3 Endothelin1 -0,113279
CALM2 AQP1 -3,046736 CASP3 FGF1 2,179099
CALM2 ATP6V0D1 0,239007 CASP3 FZD4 2,062084
CALM2 BTF3 -1,077063 CASP3 GAPDH -1,386159
CALM2 CALM2 -3,732761 CASP3 GCA 1,576945
CALM2 CASP3 -0,153562 CASP3 GDI2 0,478653
CALM2 CDYL12 0,018216 CASP3 GNAS2 -0,11571
CALM2 CFH -1,92955 CASP3 GTPBP4 0,542718
CALM2 c-Jun 2,078061 CASP3 HOXA3 -3,037106
CALM2 CLF 0,616158 CASP3 ICAM -7,712362
CALM2 CSPG 2,96628 CASP3 KLF6 1,4507
CALM2 CXCL12 0,807208 CASP3 NOS3 2,708902
CALM2 CYR61 3,233838 CASP3 PHGDH -1,457463
CALM2 Endothelin1 3,835349 CASP3 PLD -0,267839
CALM2 FGF1 -3,181601 CASP3 PRG -5,738937
CALM2 FZD4 1,619776 CASP3 PRSS23 2,727602
CALM2 GAPDH -4,815197 CASP3 RAMP3 -0,776737
CALM2 GCA 0,996761 CASP3 RHOJ 2,60178
CALM2 GDI2 -0,565448 CASP3 RPIB9 0,744745
CALM2 GNAS2 -0,789899 CASP3 SMAD2 -6,414143
CALM2 GTPBP4 -0,161493 CASP3 SMAD3 -2,728214
CALM2 HOXA3 -0,977092 CASP3 TGFb1 1,402141
CALM2 ICAM -1,051629 CASP3 TGFb-R2 0,125311
CALM2 KLF6 -1,06752 CASP3 TOR3A 0,062116
CALM2 NOS3 2,3354 CASP3 UGDH 0,97002
CALM2 PHGDH -1,105632 CDYL12 AQP1 -1,017664
CALM2 PLD -4,478745 CDYL12 ATP6V0D1 0,117312
CALM2 PRG -1,799347 CDYL12 BTF3 -0,610371
CALM2 PRSS23 3,02272 CDYL12 CALM2 -1,443827
CALM2 RAMP3 -2,231726 CDYL12 CASP3 0,170126
CALM2 RHOJ 1,081526 CDYL12 CDYL12 1,897598
CALM2 RPIB9 4,66573 CDYL12 CFH 0,032497
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Interaction 
from 
Interaction  
to 
Strenght of 
Interaction 
Interaction 
from 
Interaction  
to 
Strenght of 
Interaction 
CDYL12 c-Jun 0,303417 CFH GNAS2 -0,244501 
CDYL12 CLF -0,757179 CFH GTPBP4 -0,035682 
CDYL12 CSPG 0,250842 CFH HOXA3 0,571996 
CDYL12 CXCL12 1,487483 CFH ICAM 0,021479 
CDYL12 CYR61 0,175548 CFH KLF6 -0,009063 
CDYL12 Endothelin1 0,300286 CFH NOS3 0,242949 
CDYL12 FGF1 0,157463 CFH PHGDH -0,488553 
CDYL12 FZD4 0,261701 CFH PLD 0,074743 
CDYL12 GAPDH -1,482582 CFH PRG 0,272365 
CDYL12 GCA -0,429901 CFH PRSS23 0,780167 
CDYL12 GDI2 0,093695 CFH RAMP3 -0,000653 
CDYL12 GNAS2 -0,184377 CFH RHOJ 0,426008 
CDYL12 GTPBP4 -0,125345 CFH RPIB9 0,424983 
CDYL12 HOXA3 0,268072 CFH SMAD2 -0,085103 
CDYL12 ICAM -0,232719 CFH SMAD3 0,28332 
CDYL12 KLF6 0,319906 CFH TGFb1 0,201212 
CDYL12 NOS3 0,53664 CFH TGFb-R2 0,150135 
CDYL12 PHGDH -0,64088 CFH TOR3A -0,069621 
CDYL12 PLD -0,599745 CFH UGDH 0,429609 
CDYL12 PRG 0,322572 c-Jun AQP1 -0,064146 
CDYL12 PRSS23 0,626512 c-Jun ATP6V0D1 0,032591 
CDYL12 RAMP3 -0,051987 c-Jun BTF3 -0,381775 
CDYL12 RHOJ 0,449222 c-Jun CALM2 0,607867 
CDYL12 RPIB9 0,397418 c-Jun CASP3 0,202097 
CDYL12 SMAD2 -0,480506 c-Jun CDYL12 -0,245587 
CDYL12 SMAD3 0,401069 c-Jun CFH 0,566377 
CDYL12 TGFb1 0,246506 c-Jun c-Jun 2,125499 
CDYL12 TGFb-R2 -0,070223 c-Jun CLF -0,120851 
CDYL12 TOR3A -0,125409 c-Jun CSPG -1,254964 
CDYL12 UGDH 0,448834 c-Jun CXCL12 1,532972 
CFH AQP1 -0,929077 c-Jun CYR61 -0,444088 
CFH ATP6V0D1 0,065912 c-Jun Endothelin1 -1,14776 
CFH BTF3 -0,309593 c-Jun FGF1 1,54171 
CFH CALM2 -0,960891 c-Jun FZD4 -0,128566 
CFH CASP3 0,341853 c-Jun GAPDH -1,179839 
CFH CDYL12 0,062279 c-Jun GCA -0,581458 
CFH CFH 0,345406 c-Jun GDI2 0,172997 
CFH c-Jun 0,384285 c-Jun GNAS2 0,255923 
CFH CLF -0,718437 c-Jun GTPBP4 -0,016115 
CFH CSPG 0,601111 c-Jun HOXA3 0,109867 
CFH CXCL12 0,578945 c-Jun ICAM 0,136716 
CFH CYR61 0,164056 c-Jun KLF6 0,933512 
CFH Endothelin1 0,552145 c-Jun NOS3 -0,001442 
CFH FGF1 -0,447435 c-Jun PHGDH -0,321302 
CFH FZD4 0,238589 c-Jun PLD 0,504646 
CFH GAPDH -2,719102 c-Jun PRG 1,136098 
CFH GCA -0,652579 c-Jun PRSS23 0,140679 
CFH GDI2 0,205872 c-Jun RAMP3 0,214328 
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Interaction 
from 
Interaction  
to 
Strenght of 
Interaction 
c-Jun RPIB9 -2,183915 CSPG CASP3 0,046823
c-Jun SMAD2 -0,007251 CSPG CDYL12 -0,030937
c-Jun SMAD3 0,485082 CSPG CFH 0,048031
c-Jun TGFb1 0,11057 CSPG c-Jun 0,007172
c-Jun TGFb-R2 -0,048419 CSPG CLF -0,144475
c-Jun TOR3A -0,127674 CSPG CSPG 3,731625
c-Jun UGDH -0,55193 CSPG CXCL12 0,234863
CLF AQP1 1,92925 CSPG CYR61 0,017712
CLF ATP6V0D1 0,131621 CSPG Endothelin1 0,0181
CLF BTF3 -0,368529 CSPG FGF1 0,37619
CLF CALM2 0,452025 CSPG FZD4 -0,003139
CLF CASP3 0,506538 CSPG GAPDH -0,514425
CLF CDYL12 -0,328737 CSPG GCA -0,138902
CLF CFH 1,979011 CSPG GDI2 0,041696
CLF c-Jun -2,3076 CSPG GNAS2 -0,019624
CLF CLF -3,081079 CSPG GTPBP4 -0,020641
CLF CSPG -2,344377 CSPG HOXA3 0,071653
CLF CXCL12 2,419278 CSPG ICAM 0,013586
CLF CYR61 -3,263373 CSPG KLF6 -0,036301
CLF Endothelin1 -2,678154 CSPG NOS3 0,003981
CLF FGF1 3,782886 CSPG PHGDH -0,095599
CLF FZD4 -1,654806 CSPG PLD 0,023137
CLF GAPDH 2,696649 CSPG PRG 0,064071
CLF GCA -2,242516 CSPG PRSS23 0,116173
CLF GDI2 1,145122 CSPG RAMP3 -0,000426
CLF GNAS2 0,45734 CSPG RHOJ 0,048541
CLF GTPBP4 0,004236 CSPG RPIB9 -0,021518
CLF HOXA3 3,861057 CSPG SMAD2 -0,004167
CLF ICAM 0,571748 CSPG SMAD3 0,057168
CLF KLF6 1,576523 CSPG TGFb1 0,004105
CLF NOS3 -1,962628 CSPG TGFb-R2 -0,013688
CLF PHGDH -0,065913 CSPG TOR3A -0,005917
CLF PLD 4,656133 CSPG UGDH 0,022083
CLF PRG 3,395434 CXCL12 AQP1 0,979658
CLF PRSS23 -2,629604 CXCL12 ATP6V0D1 -0,102499
CLF RAMP3 2,458638 CXCL12 BTF3 0,040212
CLF RHOJ -0,332018 CXCL12 CALM2 0,352665
CLF RPIB9 -1,715203 CXCL12 CASP3 0,169904
CLF SMAD2 1,019112 CXCL12 CDYL12 0,254639
CLF SMAD3 -0,894491 CXCL12 CFH -0,019394
CLF TGFb1 -0,968707 CXCL12 c-Jun 0,044251
CLF TGFb-R2 -0,633826 CXCL12 CLF 0,470731
CLF TOR3A 0,720497 CXCL12 CSPG -0,433789
CLF UGDH -2,052853 CXCL12 CXCL12 1,068447
CSPG AQP1 -0,127365 CXCL12 CYR61 0,123507
CSPG ATP6V0D1 -0,002376 CXCL12 Endothelin1 0,28751
CSPG BTF3 -0,074958 CXCL12 FGF1 -0,132652
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from 
Interaction  
to 
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CXCL12 FZD4 0,049283 CYR61 PLD 0,799185 
CXCL12 GAPDH -0,193411 CYR61 PRG 0,620565 
CXCL12 GCA 0,2288 CYR61 PRSS23 -1,150767 
CXCL12 GDI2 -0,106753 CYR61 RAMP3 2,999542 
CXCL12 GNAS2 0,025759 CYR61 RHOJ -0,386008 
CXCL12 GTPBP4 0,029552 CYR61 RPIB9 -2,333872 
CXCL12 HOXA3 0,041873 CYR61 SMAD2 1,122306 
CXCL12 ICAM 0,473598 CYR61 SMAD3 -0,156653 
CXCL12 KLF6 -0,239119 CYR61 TGFb1 0,39706 
CXCL12 NOS3 -0,02826 CYR61 TGFb-R2 0,488599 
CXCL12 PHGDH 0,189017 CYR61 TOR3A 0,067978 
CXCL12 PLD 0,072361 CYR61 UGDH -0,938486 
CXCL12 PRG -0,030393 Endothelin1 AQP1 -1,423115 
CXCL12 PRSS23 -0,067909 Endothelin1 ATP6V0D1 0,06901 
CXCL12 RAMP3 -0,107473 Endothelin1 BTF3 -0,234424 
CXCL12 RHOJ -0,101821 Endothelin1 CALM2 0,738925 
CXCL12 RPIB9 0,532244 Endothelin1 CASP3 0,180086 
CXCL12 SMAD2 0,416041 Endothelin1 CDYL12 -0,154949 
CXCL12 SMAD3 0,066343 Endothelin1 CFH -0,09834 
CXCL12 TGFb1 0,151731 Endothelin1 c-Jun 1,243444 
CXCL12 TGFb-R2 0,322165 Endothelin1 CLF 2,024652 
CXCL12 TOR3A 0,052434 Endothelin1 CSPG -0,210143 
CXCL12 UGDH 0,073585 Endothelin1 CXCL12 0,391085 
CYR61 AQP1 1,733734 Endothelin1 CYR61 1,118653 
CYR61 ATP6V0D1 -0,276139 Endothelin1 Endothelin1 0,44604 
CYR61 BTF3 0,91894 Endothelin1 FGF1 0,074869 
CYR61 CALM2 1,517557 Endothelin1 FZD4 0,861509 
CYR61 CASP3 0,196327 Endothelin1 GAPDH -1,313102 
CYR61 CDYL12 0,083023 Endothelin1 GCA 0,636822 
CYR61 CFH 2,369235 Endothelin1 GDI2 -0,345289 
CYR61 c-Jun -0,699378 Endothelin1 GNAS2 -0,036484 
CYR61 CLF 1,035112 Endothelin1 GTPBP4 -0,031419 
CYR61 CSPG -2,217062 Endothelin1 HOXA3 -1,073105 
CYR61 CXCL12 -2,091655 Endothelin1 ICAM 0,005312 
CYR61 CYR61 -0,005309 Endothelin1 KLF6 0,367888 
CYR61 Endothelin1 -1,162037 Endothelin1 NOS3 1,072445 
CYR61 FGF1 1,954061 Endothelin1 PHGDH -0,320208 
CYR61 FZD4 -0,658798 Endothelin1 PLD -1,523676 
CYR61 GAPDH 2,192965 Endothelin1 PRG -0,803353 
CYR61 GCA -0,204767 Endothelin1 PRSS23 1,94045 
CYR61 GDI2 -0,216719 Endothelin1 RAMP3 -0,880815 
CYR61 GNAS2 0,48172 Endothelin1 RHOJ 0,586128 
CYR61 GTPBP4 -0,015793 Endothelin1 RPIB9 -2,168576 
CYR61 HOXA3 -0,064949 Endothelin1 SMAD2 -0,251569 
CYR61 ICAM 1,315667 Endothelin1 SMAD3 1,230222 
CYR61 KLF6 0,34182 Endothelin1 TGFb1 0,450065 
CYR61 NOS3 -0,525726 Endothelin1 TGFb-R2 0,117336 
CYR61 PHGDH 0,753908 Endothelin1 TOR3A -0,303502 
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Endothelin1 UGDH 0,298661 FZD4 CXCL12 1,262295
FGF1 AQP1 0,090385 FZD4 CYR61 -0,05394
FGF1 ATP6V0D1 0,069161 FZD4 Endothelin1 0,295482
FGF1 BTF3 -0,052939 FZD4 FGF1 -0,106148
FGF1 CALM2 0,012379 FZD4 FZD4 2,128543
FGF1 CASP3 0,159011 FZD4 GAPDH -1,96532
FGF1 CDYL12 0,196979 FZD4 GCA -0,936292
FGF1 CFH 0,004089 FZD4 GDI2 0,315538
FGF1 c-Jun -0,006599 FZD4 GNAS2 -0,199054
FGF1 CLF -0,241329 FZD4 GTPBP4 -0,057107
FGF1 CSPG -0,324237 FZD4 HOXA3 0,545993
FGF1 CXCL12 0,047263 FZD4 ICAM -0,10025
FGF1 CYR61 0,085685 FZD4 KLF6 0,175129
FGF1 Endothelin1 0,006814 FZD4 NOS3 0,086504
FGF1 FGF1 2,515363 FZD4 PHGDH -0,503613
FGF1 FZD4 0,085373 FZD4 PLD 0,277162
FGF1 GAPDH -0,00809 FZD4 PRG 0,579215
FGF1 GCA -0,105136 FZD4 PRSS23 0,465435
FGF1 GDI2 0,126447 FZD4 RAMP3 0,150172
FGF1 GNAS2 0,036397 FZD4 RHOJ 0,322986
FGF1 GTPBP4 0,003615 FZD4 RPIB9 0,537328
FGF1 HOXA3 0,239667 FZD4 SMAD2 -0,139913
FGF1 ICAM 0,046307 FZD4 SMAD3 0,283262
FGF1 KLF6 0,23843 FZD4 TGFb1 -0,178481
FGF1 NOS3 0,055732 FZD4 TGFb-R2 -0,231483
FGF1 PHGDH -0,058264 FZD4 TOR3A -0,05375
FGF1 PLD 0,293499 FZD4 UGDH 0,236679
FGF1 PRG 0,255403 GAPDH AQP1 -1,285852
FGF1 PRSS23 -0,119329 GAPDH ATP6V0D1 0,062921
FGF1 RAMP3 -0,06658 GAPDH BTF3 -0,290265
FGF1 RHOJ 0,08113 GAPDH CALM2 -0,721993
FGF1 RPIB9 0,091172 GAPDH CASP3 0,592818
FGF1 SMAD2 0,107148 GAPDH CDYL12 -0,018925
FGF1 SMAD3 0,143185 GAPDH CFH -0,336479
FGF1 TGFb1 0,035926 GAPDH c-Jun 0,79265
FGF1 TGFb-R2 -0,014054 GAPDH CLF -0,322811
FGF1 TOR3A 0,054268 GAPDH CSPG 0,400566
FGF1 UGDH -0,010446 GAPDH CXCL12 0,62672
FZD4 AQP1 -0,853477 GAPDH CYR61 0,494133
FZD4 ATP6V0D1 0,069382 GAPDH Endothelin1 0,506889
FZD4 BTF3 -0,456124 GAPDH FGF1 -0,330092
FZD4 CALM2 -0,994436 GAPDH FZD4 0,308799
FZD4 CASP3 0,423494 GAPDH GAPDH 0,050888
FZD4 CDYL12 -0,104829 GAPDH GCA 0,12856
FZD4 CFH -0,826351 GAPDH GDI2 -0,003754
FZD4 c-Jun 0,159408 GAPDH GNAS2 -0,136431
FZD4 CLF -1,100342 GAPDH GTPBP4 0,027262
FZD4 CSPG 0,546913 GAPDH HOXA3 0,385663
 
 
 
 - 90 -
Interaction 
from 
Interaction  
to 
Strenght of 
Interaction 
Interaction 
from 
Interaction  
to 
Strenght of 
Interaction 
GAPDH ICAM 0,419292 GCA SMAD3 0,117338 
GAPDH KLF6 0,202552 GCA TGFb1 0,00773 
GAPDH NOS3 0,326284 GCA TGFb-R2 -0,093554 
GAPDH PHGDH -0,321702 GCA TOR3A -0,002917 
GAPDH PLD -0,604335 GCA UGDH 0,040334 
GAPDH PRG 0,224281 GDI2 AQP1 -0,522203 
GAPDH PRSS23 0,968161 GDI2 ATP6V0D1 0,030233 
GAPDH RAMP3 -0,317611 GDI2 BTF3 -0,098632 
GAPDH RHOJ 0,248126 GDI2 CALM2 0,234539 
GAPDH RPIB9 -0,045898 GDI2 CASP3 0,19451 
GAPDH SMAD2 -0,007294 GDI2 CDYL12 -0,043086 
GAPDH SMAD3 0,777137 GDI2 CFH -0,105751 
GAPDH TGFb1 0,117956 GDI2 c-Jun 0,446012 
GAPDH TGFb-R2 0,057832 GDI2 CLF 0,684758 
GAPDH TOR3A -0,220995 GDI2 CSPG -0,118149 
GAPDH UGDH 0,428592 GDI2 CXCL12 0,211289 
GCA AQP1 -0,198923 GDI2 CYR61 0,409766 
GCA ATP6V0D1 0,057357 GDI2 Endothelin1 0,048475 
GCA BTF3 -0,284124 GDI2 FGF1 0,059297 
GCA CALM2 -0,514125 GDI2 FZD4 0,298291 
GCA CASP3 0,10447 GDI2 GAPDH -0,484308 
GCA CDYL12 -0,105097 GDI2 GCA 0,210284 
GCA CFH 0,06698 GDI2 GDI2 1,886837 
GCA c-Jun -0,077142 GDI2 GNAS2 0,027886 
GCA CLF -0,892572 GDI2 GTPBP4 -0,011329 
GCA CSPG -0,153859 GDI2 HOXA3 -0,293912 
GCA CXCL12 0,836269 GDI2 ICAM 0,040684 
GCA CYR61 -0,060192 GDI2 KLF6 0,166866 
GCA Endothelin1 0,016283 GDI2 NOS3 0,782998 
GCA FGF1 0,475266 GDI2 PHGDH -0,114569 
GCA FZD4 0,040527 GDI2 PLD -0,619083 
GCA GAPDH -0,534175 GDI2 PRG -0,139531 
GCA GCA 1,996602 GDI2 PRSS23 0,7428 
GCA GDI2 0,242542 GDI2 RAMP3 -0,336962 
GCA GNAS2 -0,037891 GDI2 RHOJ 0,221758 
GCA GTPBP4 -0,010385 GDI2 RPIB9 -0,841091 
GCA HOXA3 0,457223 GDI2 SMAD2 0,00147 
GCA ICAM -0,128633 GDI2 SMAD3 0,509539 
GCA KLF6 0,331737 GDI2 TGFb1 0,180345 
GCA NOS3 0,077197 GDI2 TGFb-R2 0,047316 
GCA PHGDH -0,367007 GDI2 TOR3A -0,102458 
GCA PLD 0,337256 GDI2 UGDH 0,112341 
GCA PRG 0,373063 GNAS2 AQP1 0,631276 
GCA PRSS23 0,125945 GNAS2 ATP6V0D1 -0,043007 
GCA RAMP3 0,096418 GNAS2 BTF3 0,186395 
GCA RHOJ 0,259841 GNAS2 CALM2 1,438364 
GCA RPIB9 0,286851 GNAS2 CASP3 -0,082553 
GCA SMAD2 -0,118574 GNAS2 CDYL12 -0,153049 
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GNAS2 CFH 1,257652 GTPBP4 GDI2 0,389734
GNAS2 c-Jun -0,341702 GTPBP4 GNAS2 -0,012982
GNAS2 CLF 0,836314 GTPBP4 GTPBP4 1,89768
GNAS2 CSPG 0,077801 GTPBP4 HOXA3 0,644008
GNAS2 CXCL12 -0,076881 GTPBP4 ICAM -0,158091
GNAS2 CYR61 -0,74119 GTPBP4 KLF6 0,565255
GNAS2 Endothelin1 -1,031415 GTPBP4 NOS3 -0,270796
GNAS2 FGF1 1,052674 GTPBP4 PHGDH -0,499135
GNAS2 FZD4 -0,104385 GTPBP4 PLD 0,964364
GNAS2 GAPDH 1,987186 GTPBP4 PRG 1,068494
GNAS2 GCA -0,335394 GTPBP4 PRSS23 -0,234567
GNAS2 GDI2 -0,127158 GTPBP4 RAMP3 0,41166
GNAS2 GNAS2 2,187287 GTPBP4 RHOJ 0,242985
GNAS2 GTPBP4 0,040727 GTPBP4 RPIB9 0,267293
GNAS2 HOXA3 -0,329482 GTPBP4 SMAD2 -0,041879
GNAS2 ICAM 0,39632 GTPBP4 SMAD3 -0,032841
GNAS2 KLF6 0,592359 GTPBP4 TGFb1 -0,392196
GNAS2 NOS3 -0,421791 GTPBP4 TGFb-R2 -0,185649
GNAS2 PHGDH 0,127728 GTPBP4 TOR3A 0,191929
GNAS2 PLD 0,501432 GTPBP4 UGDH -0,025925
GNAS2 PRG 0,335174 HOXA3 AQP1 -0,4941
GNAS2 PRSS23 -0,436322 HOXA3 ATP6V0D1 0,061754
GNAS2 RAMP3 2,226801 HOXA3 BTF3 -0,14705
GNAS2 RHOJ -0,012764 HOXA3 CALM2 -0,003165
GNAS2 RPIB9 -2,293562 HOXA3 CASP3 0,129217
GNAS2 SMAD2 0,334785 HOXA3 CDYL12 -0,109686
GNAS2 SMAD3 0,122901 HOXA3 CFH 0,052311
GNAS2 TGFb1 0,231002 HOXA3 c-Jun 0,347007
GNAS2 TGFb-R2 0,071475 HOXA3 CLF 0,238254
GNAS2 TOR3A -0,214781 HOXA3 CSPG -0,120706
GNAS2 UGDH -0,593696 HOXA3 CXCL12 0,299946
GTPBP4 AQP1 -0,019944 HOXA3 CYR61 0,277071
GTPBP4 ATP6V0D1 0,177547 HOXA3 Endothelin1 0,069464
GTPBP4 BTF3 -0,511736 HOXA3 FGF1 0,203323
GTPBP4 CALM2 -0,780322 HOXA3 FZD4 0,239946
GTPBP4 CASP3 0,214397 HOXA3 GAPDH -0,721046
GTPBP4 CDYL12 -0,257282 HOXA3 GCA 0,066035
GTPBP4 CFH 0,357408 HOXA3 GDI2 -0,039585
GTPBP4 c-Jun -0,433004 HOXA3 GNAS2 -0,008812
GTPBP4 CLF -1,480965 HOXA3 GTPBP4 -0,042365
GTPBP4 CSPG -0,249621 HOXA3 HOXA3 2,284825
GTPBP4 CXCL12 1,457217 HOXA3 ICAM -0,057733
GTPBP4 CYR61 -0,46138 HOXA3 KLF6 0,232501
GTPBP4 Endothelin1 -0,202608 HOXA3 NOS3 0,3172
GTPBP4 FGF1 1,067299 HOXA3 PHGDH -0,255345
GTPBP4 FZD4 -0,262349 HOXA3 PLD -0,411843
GTPBP4 GAPDH -0,162759 HOXA3 PRG -0,015214
GTPBP4 GCA -0,702158 HOXA3 PRSS23 0,526719
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HOXA3 RAMP3 -0,206556 KLF6 BTF3 0,813969 
HOXA3 RHOJ 0,284675 KLF6 CALM2 1,30467 
HOXA3 RPIB9 -0,458962 KLF6 CASP3 0,459868 
HOXA3 SMAD2 -0,116524 KLF6 CDYL12 0,259899 
HOXA3 SMAD3 0,426192 KLF6 CFH 1,022732 
HOXA3 TGFb1 0,116499 KLF6 c-Jun -0,479879 
HOXA3 TGFb-R2 0,0281 KLF6 CLF 0,492448 
HOXA3 TOR3A -0,122777 KLF6 CSPG 1,286562 
HOXA3 UGDH 0,166775 KLF6 CXCL12 -1,892251 
ICAM AQP1 -0,055842 KLF6 CYR61 -0,761481 
ICAM ATP6V0D1 0,160282 KLF6 Endothelin1 -0,913173 
ICAM BTF3 -0,42817 KLF6 FGF1 0,126154 
ICAM CALM2 -0,098076 KLF6 FZD4 -0,367284 
ICAM CASP3 0,155861 KLF6 GAPDH 2,549512 
ICAM CDYL12 -0,241314 KLF6 GCA 0,156962 
ICAM CFH 0,620361 KLF6 GDI2 -0,120326 
ICAM c-Jun -0,499641 KLF6 GNAS2 0,258047 
ICAM CLF -0,898077 KLF6 GTPBP4 -0,0846 
ICAM CSPG -0,677438 KLF6 HOXA3 0,469992 
ICAM CXCL12 1,345553 KLF6 ICAM 1,068114 
ICAM CYR61 -0,493526 KLF6 KLF6 1,226434 
ICAM Endothelin1 -0,63608 KLF6 NOS3 -0,532306 
ICAM FGF1 1,334682 KLF6 PHGDH 0,166961 
ICAM FZD4 -0,15303 KLF6 PLD 1,211519 
ICAM GAPDH -0,017039 KLF6 PRG 0,926734 
ICAM GCA -0,59269 KLF6 PRSS23 -1,269263 
ICAM GDI2 0,372268 KLF6 RAMP3 0,488305 
ICAM GNAS2 0,086516 KLF6 RHOJ -0,331237 
ICAM GTPBP4 0,002773 KLF6 RPIB9 -1,329022 
ICAM HOXA3 0,337033 KLF6 SMAD2 1,0852 
ICAM ICAM 1,642936 KLF6 SMAD3 0,057792 
ICAM KLF6 0,653758 KLF6 TGFb1 0,033117 
ICAM NOS3 -0,052836 KLF6 TGFb-R2 0,427413 
ICAM PHGDH -0,537722 KLF6 TOR3A 0,172837 
ICAM PLD 0,987355 KLF6 UGDH -0,72825 
ICAM PRG 0,999998 NOS3 AQP1 0,194468 
ICAM PRSS23 -0,12977 NOS3 ATP6V0D1 0,025143 
ICAM RAMP3 0,381481 NOS3 BTF3 -0,237475 
ICAM RHOJ 0,311002 NOS3 CALM2 0,178299 
ICAM RPIB9 -0,735808 NOS3 CASP3 0,134759 
ICAM SMAD2 0,020781 NOS3 CDYL12 -0,208658 
ICAM SMAD3 0,135896 NOS3 CFH 0,34896 
ICAM TGFb1 -0,099432 NOS3 c-Jun 0,152776 
ICAM TGFb-R2 -0,192266 NOS3 CLF 0,041936 
ICAM TOR3A 0,198179 NOS3 CSPG -0,688913 
ICAM UGDH -0,339851 NOS3 CXCL12 0,962163 
KLF6 AQP1 1,664461 NOS3 CYR61 -0,14822 
KLF6 ATP6V0D1 -0,164714 NOS3 Endothelin1 -0,357291 
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NOS3 FGF1 0,792039 PHGDH PHGDH 1,853456
NOS3 FZD4 0,169745 PHGDH PLD 0,992965
NOS3 GAPDH -0,562523 PHGDH PRG 0,739949
NOS3 GCA -0,213649 PHGDH PRSS23 -0,283235
NOS3 GDI2 0,067631 PHGDH RAMP3 0,383569
NOS3 GNAS2 0,046218 PHGDH RHOJ 0,257652
NOS3 GTPBP4 -0,092357 PHGDH RPIB9 -0,383497
NOS3 HOXA3 -0,011407 PHGDH SMAD2 -0,02565
NOS3 ICAM 0,077071 PHGDH SMAD3 -0,011334
NOS3 KLF6 0,293661 PHGDH TGFb1 -0,260175
NOS3 NOS3 2,098091 PHGDH TGFb-R2 -0,25053
NOS3 PHGDH -0,261336 PHGDH TOR3A 0,245874
NOS3 PLD 0,060515 PHGDH UGDH -0,242587
NOS3 PRG 0,204702 PLD AQP1 -1,304656
NOS3 PRSS23 0,48024 PLD ATP6V0D1 0,07524
NOS3 RAMP3 0,110214 PLD BTF3 -0,252284
NOS3 RHOJ 0,212726 PLD CALM2 1,249145
NOS3 RPIB9 -1,233677 PLD CASP3 0,134269
NOS3 SMAD2 -0,049944 PLD CDYL12 -0,338918
NOS3 SMAD3 0,431952 PLD CFH 0,559681
NOS3 TGFb1 0,11867 PLD c-Jun 0,965911
NOS3 TGFb-R2 -0,06661 PLD CLF 1,604756
NOS3 TOR3A -0,054059 PLD CSPG -0,720347
NOS3 UGDH -0,210265 PLD CXCL12 0,594866
PHGDH AQP1 0,192622 PLD CYR61 0,784333
PHGDH ATP6V0D1 0,160081 PLD Endothelin1 -0,523273
PHGDH BTF3 -0,234119 PLD FGF1 0,863824
PHGDH CALM2 0,168511 PLD FZD4 0,67139
PHGDH CASP3 -0,036258 PLD GAPDH -1,376722
PHGDH CDYL12 -0,18084 PLD GCA 0,504969
PHGDH CFH 0,530371 PLD GDI2 -0,307012
PHGDH c-Jun -0,421911 PLD GNAS2 0,107368
PHGDH CLF -0,946539 PLD GTPBP4 -0,111398
PHGDH CSPG -0,641865 PLD HOXA3 -0,969137
PHGDH CXCL12 0,691945 PLD ICAM -0,115976
PHGDH CYR61 -0,497396 PLD KLF6 0,646984
PHGDH Endothelin1 -0,426788 PLD NOS3 0,887649
PHGDH FGF1 1,327598 PLD PHGDH -0,530245
PHGDH FZD4 -0,17661 PLD PLD -0,709276
PHGDH GAPDH -0,012926 PLD PRG -0,397471
PHGDH GCA -0,455638 PLD PRSS23 1,642682
PHGDH GDI2 0,317786 PLD RAMP3 -0,686776
PHGDH GNAS2 0,098245 PLD RHOJ 0,644232
PHGDH GTPBP4 0,085801 PLD RPIB9 -2,768838
PHGDH HOXA3 0,36762 PLD SMAD2 -0,277574
PHGDH ICAM -0,27431 PLD SMAD3 1,219833
PHGDH KLF6 0,611256 PLD TGFb1 0,427115
PHGDH NOS3 -0,205624 PLD TGFb-R2 0,163462
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PLD TOR3A -0,303559 PRSS23 CSPG 1,817921 
PLD UGDH 0,156602 PRSS23 CXCL12 -3,413204 
PRG AQP1 0,879461 PRSS23 CYR61 1,253514 
PRG ATP6V0D1 0,139465 PRSS23 Endothelin1 2,842801 
PRG BTF3 0,422625 PRSS23 FGF1 -2,538473 
PRG CALM2 -1,656693 PRSS23 FZD4 0,018764 
PRG CASP3 0,060645 PRSS23 GAPDH -1,317217 
PRG CDYL12 0,581995 PRSS23 GCA 0,232562 
PRG CFH -1,450461 PRSS23 GDI2 0,236799 
PRG c-Jun -0,220247 PRSS23 GNAS2 -0,291544 
PRG CLF -0,298701 PRSS23 GTPBP4 0,070735 
PRG CSPG 1,721634 PRSS23 HOXA3 0,740413 
PRG CXCL12 -2,66132 PRSS23 ICAM -0,039704 
PRG CYR61 1,282092 PRSS23 KLF6 -1,375956 
PRG Endothelin1 2,617896 PRSS23 NOS3 -0,139539 
PRG FGF1 -2,585011 PRSS23 PHGDH 0,365794 
PRG FZD4 0,333999 PRSS23 PLD -0,680746 
PRG GAPDH 0,152326 PRSS23 PRG -0,311732 
PRG GCA 0,880418 PRSS23 PRSS23 0,847285 
PRG GDI2 -0,065074 PRSS23 RAMP3 -0,880577 
PRG GNAS2 -0,324713 PRSS23 RHOJ -0,258409 
PRG GTPBP4 0,143221 PRSS23 RPIB9 7,857261 
PRG HOXA3 0,242248 PRSS23 SMAD2 0,161709 
PRG ICAM -0,167208 PRSS23 SMAD3 -0,935454 
PRG KLF6 -1,637824 PRSS23 TGFb1 -0,414377 
PRG NOS3 0,288936 PRSS23 TGFb-R2 0,050703 
PRG PHGDH 0,672652 PRSS23 TOR3A 0,423672 
PRG PLD -0,980209 PRSS23 UGDH 1,333416 
PRG PRG 1,456033 RAMP3 AQP1 -0,260592 
PRG PRSS23 -0,270675 RAMP3 ATP6V0D1 0,019166 
PRG RAMP3 -0,82963 RAMP3 BTF3 -0,150158 
PRG RHOJ -0,228541 RAMP3 CALM2 -0,354093 
PRG RPIB9 6,210309 RAMP3 CASP3 0,125197 
PRG SMAD2 0,209534 RAMP3 CDYL12 -0,057261 
PRG SMAD3 -0,562137 RAMP3 CFH -0,289608 
PRG TGFb1 -0,153684 RAMP3 c-Jun 0,066469 
PRG TGFb-R2 0,103448 RAMP3 CLF -0,273036 
PRG TOR3A 0,298233 RAMP3 CSPG 0,201877 
PRG UGDH 1,348567 RAMP3 CXCL12 0,373445 
PRSS23 AQP1 1,008426 RAMP3 CYR61 0,006419 
PRSS23 ATP6V0D1 0,053409 RAMP3 Endothelin1 0,0293 
PRSS23 BTF3 0,613626 RAMP3 FGF1 -0,036553 
PRSS23 CALM2 -2,163368 RAMP3 FZD4 0,054218 
PRSS23 CASP3 0,076568 RAMP3 GAPDH -0,697487 
PRSS23 CDYL12 0,672295 RAMP3 GCA -0,095663 
PRSS23 CFH -1,425859 RAMP3 GDI2 0,095051 
PRSS23 c-Jun 0,075995 RAMP3 GNAS2 -0,068126 
PRSS23 CLF -1,05331 RAMP3 GTPBP4 -0,03857 
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RAMP3 HOXA3 0,183082 RHOJ SMAD2 -0,33421
RAMP3 ICAM -0,073403 RHOJ SMAD3 0,313565
RAMP3 KLF6 -0,010189 RHOJ TGFb1 -0,08597
RAMP3 NOS3 0,025804 RHOJ TGFb-R2 -0,229026
RAMP3 PHGDH -0,180068 RHOJ TOR3A -0,088269
RAMP3 PLD 0,064598 RHOJ UGDH 0,316683
RAMP3 PRG 0,151859 RPIB9 AQP1 -0,930272
RAMP3 PRSS23 0,121545 RPIB9 ATP6V0D1 0,110544
RAMP3 RAMP3 3,575295 RPIB9 BTF3 -0,682635
RAMP3 RHOJ 0,11189 RPIB9 CALM2 0,162924
RAMP3 RPIB9 0,160901 RPIB9 CASP3 0,292656
RAMP3 SMAD2 -0,072731 RPIB9 CDYL12 -0,466737
RAMP3 SMAD3 0,115017 RPIB9 CFH 1,010395
RAMP3 TGFb1 -0,067827 RPIB9 c-Jun -0,083738
RAMP3 TGFb-R2 -0,063445 RPIB9 CLF -0,412118
RAMP3 TOR3A 0,011063 RPIB9 CSPG -0,916101
RAMP3 UGDH 0,077934 RPIB9 CXCL12 2,479657
RHOJ AQP1 -1,280362 RPIB9 CYR61 -0,509635
RHOJ ATP6V0D1 0,091783 RPIB9 Endothelin1 -1,131415
RHOJ BTF3 -0,663887 RPIB9 FGF1 1,620557
RHOJ CALM2 -0,887787 RPIB9 FZD4 0,055868
RHOJ CASP3 0,268817 RPIB9 GAPDH -0,777969
RHOJ CDYL12 -0,182935 RPIB9 GCA -0,654921
RHOJ CFH -1,151993 RPIB9 GDI2 0,178603
RHOJ c-Jun 0,295836 RPIB9 GNAS2 0,090822
RHOJ CLF -0,96468 RPIB9 GTPBP4 -0,061006
RHOJ CSPG 0,776246 RPIB9 HOXA3 0,219708
RHOJ CXCL12 1,921979 RPIB9 ICAM -0,121627
RHOJ CYR61 0,131644 RPIB9 KLF6 0,974219
RHOJ Endothelin1 0,197263 RPIB9 NOS3 0,249131
RHOJ FGF1 -0,292086 RPIB9 PHGDH -0,74399
RHOJ FZD4 0,26688 RPIB9 PLD 0,50319
RHOJ GAPDH -1,982485 RPIB9 PRG 0,863141
RHOJ GCA -0,682826 RPIB9 PRSS23 0,180337
RHOJ GDI2 0,277609 RPIB9 RAMP3 0,362849
RHOJ GNAS2 -0,21972 RPIB9 RHOJ 0,554255
RHOJ GTPBP4 -0,070687 RPIB9 RPIB9 -0,947515
RHOJ HOXA3 0,486262 RPIB9 SMAD2 -0,133732
RHOJ ICAM -0,249554 RPIB9 SMAD3 0,769392
RHOJ KLF6 0,227239 RPIB9 TGFb1 0,247692
RHOJ NOS3 0,386474 RPIB9 TGFb-R2 -0,054799
RHOJ PHGDH -0,509805 RPIB9 TOR3A -0,234201
RHOJ PLD -0,122358 RPIB9 UGDH -0,476633
RHOJ PRG 0,342943 SMAD2 AQP1 -0,171812
RHOJ PRSS23 0,683442 SMAD2 ATP6V0D1 0,010975
RHOJ RAMP3 0,018729 SMAD2 BTF3 -0,265004
RHOJ RHOJ 2,49185 SMAD2 CALM2 -0,183287
RHOJ RPIB9 0,380013 SMAD2 CASP3 0,174729
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to 
Strenght of 
Interaction 
SMAD2 CDYL12 -0,140778 SMAD3 GCA -0,259429 
SMAD2 CFH 0,44157 SMAD3 GDI2 0,048709 
SMAD2 c-Jun -0,106852 SMAD3 GNAS2 -0,097178 
SMAD2 CLF -0,494962 SMAD3 GTPBP4 -0,072951 
SMAD2 CSPG -0,477231 SMAD3 HOXA3 0,324979 
SMAD2 CXCL12 0,985341 SMAD3 ICAM 0,218015 
SMAD2 CYR61 -0,378648 SMAD3 KLF6 0,417051 
SMAD2 Endothelin1 -0,476078 SMAD3 NOS3 0,121789 
SMAD2 FGF1 0,856169 SMAD3 PHGDH -0,261475 
SMAD2 FZD4 -0,080911 SMAD3 PLD -0,205723 
SMAD2 GAPDH -0,083507 SMAD3 PRG 0,46935 
SMAD2 GCA -0,393349 SMAD3 PRSS23 0,238448 
SMAD2 GDI2 0,174495 SMAD3 RAMP3 0,154578 
SMAD2 GNAS2 0,08878 SMAD3 RHOJ 0,143075 
SMAD2 GTPBP4 -0,046543 SMAD3 RPIB9 -0,302382 
SMAD2 HOXA3 0,417238 SMAD3 SMAD2 -0,019514 
SMAD2 ICAM 0,034694 SMAD3 SMAD3 2,33675 
SMAD2 KLF6 0,44373 SMAD3 TGFb1 0,076864 
SMAD2 NOS3 0,049899 SMAD3 TGFb-R2 -0,104073 
SMAD2 PHGDH -0,320187 SMAD3 TOR3A -0,085956 
SMAD2 PLD 0,437831 SMAD3 UGDH 0,052293 
SMAD2 PRG 0,712885 TGFb1 AQP1 -0,04787 
SMAD2 PRSS23 -0,090107 TGFb1 ATP6V0D1 0,109299 
SMAD2 RAMP3 0,255614 TGFb1 BTF3 -0,371438 
SMAD2 RHOJ 0,258073 TGFb1 CALM2 -0,633426 
SMAD2 RPIB9 -0,457652 TGFb1 CASP3 0,026022 
SMAD2 SMAD2 1,966927 TGFb1 CDYL12 -0,099515 
SMAD2 SMAD3 0,220741 TGFb1 CFH 0,137997 
SMAD2 TGFb1 0,03644 TGFb1 c-Jun -0,361341 
SMAD2 TGFb-R2 -0,010061 TGFb1 CLF -1,433114 
SMAD2 TOR3A 0,07211 TGFb1 CSPG 1,12179 
SMAD2 UGDH -0,247075 TGFb1 CXCL12 1,041784 
SMAD3 AQP1 -0,470039 TGFb1 CYR61 -0,272378 
SMAD3 ATP6V0D1 0,035381 TGFb1 Endothelin1 -0,18914 
SMAD3 BTF3 -0,290751 TGFb1 FGF1 0,321726 
SMAD3 CALM2 -0,51931 TGFb1 FZD4 -0,032205 
SMAD3 CASP3 0,417966 TGFb1 GAPDH 0,153084 
SMAD3 CDYL12 -0,09506 TGFb1 GCA -0,54898 
SMAD3 CFH -0,13046 TGFb1 GDI2 0,388874 
SMAD3 c-Jun 0,248093 TGFb1 GNAS2 -0,032829 
SMAD3 CLF -0,436647 TGFb1 GTPBP4 -0,005989 
SMAD3 CSPG 1,235187 TGFb1 HOXA3 0,735693 
SMAD3 CXCL12 0,865239 TGFb1 ICAM -0,32212 
SMAD3 CYR61 -0,122251 TGFb1 KLF6 0,67219 
SMAD3 Endothelin1 -0,045374 TGFb1 NOS3 0,028084 
SMAD3 FGF1 -0,125278 TGFb1 PHGDH -0,407542 
SMAD3 FZD4 0,115177 TGFb1 PLD 0,651457 
SMAD3 GAPDH 0,120993 TGFb1 PRG 0,588396 
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Interaction 
from 
Interaction  
to 
Strenght of 
Interaction 
Interaction 
from 
Interaction  
to 
Strenght of 
Interaction 
TGFb1 PRSS23 -0,298462 TOR3A ATP6V0D1 0,068918
TGFb1 RAMP3 0,265818 TOR3A BTF3 -0,413956
TGFb1 RHOJ 0,316043 TOR3A CALM2 -1,060599
TGFb1 RPIB9 0,701872 TOR3A CASP3 0,289129
TGFb1 SMAD2 -0,205828 TOR3A CDYL12 -0,099789
TGFb1 SMAD3 -0,037211 TOR3A CFH -0,813397
TGFb1 TGFb1 1,633198 TOR3A c-Jun 0,194724
TGFb1 TGFb-R2 -0,154977 TOR3A CLF -1,00681
TGFb1 TOR3A 0,101178 TOR3A CSPG 0,609698
TGFb1 UGDH -0,038122 TOR3A CXCL12 1,026558
TGFb-R2 AQP1 -0,650353 TOR3A CYR61 0,082552
TGFb-R2 ATP6V0D1 0,151817 TOR3A Endothelin1 0,463403
TGFb-R2 BTF3 -0,504576 TOR3A FGF1 -0,223439
TGFb-R2 CALM2 -1,424873 TOR3A FZD4 0,142345
TGFb-R2 CASP3 0,078106 TOR3A GAPDH -1,895986
TGFb-R2 CDYL12 0,059089 TOR3A GCA -0,736713
TGFb-R2 CFH -2,136859 TOR3A GDI2 0,275635
TGFb-R2 c-Jun 0,101163 TOR3A GNAS2 -0,222805
TGFb-R2 CLF -1,336576 TOR3A GTPBP4 -0,04841
TGFb-R2 CSPG 1,016944 TOR3A HOXA3 0,612508
TGFb-R2 CXCL12 0,954057 TOR3A ICAM -0,16147
TGFb-R2 CYR61 0,230689 TOR3A KLF6 0,157412
TGFb-R2 Endothelin1 0,715016 TOR3A NOS3 0,18301
TGFb-R2 FGF1 -0,477687 TOR3A PHGDH -0,483153
TGFb-R2 FZD4 0,332204 TOR3A PLD 0,12787
TGFb-R2 GAPDH -0,819272 TOR3A PRG 0,37954
TGFb-R2 GCA -0,593891 TOR3A PRSS23 0,410234
TGFb-R2 GDI2 0,392268 TOR3A RAMP3 0,056591
TGFb-R2 GNAS2 -0,223673 TOR3A RHOJ 0,496005
TGFb-R2 GTPBP4 -0,046167 TOR3A RPIB9 0,872244
TGFb-R2 HOXA3 0,742079 TOR3A SMAD2 -0,190656
TGFb-R2 ICAM -0,463773 TOR3A SMAD3 0,213453
TGFb-R2 KLF6 0,250044 TOR3A TGFb1 -0,136906
TGFb-R2 NOS3 0,402942 TOR3A TGFb-R2 -0,165327
TGFb-R2 PHGDH -0,271544 TOR3A TOR3A 1,904106
TGFb-R2 PLD 0,121529 TOR3A UGDH 0,344782
TGFb-R2 PRG 0,124962 UGDH AQP1 0,284509
TGFb-R2 PRSS23 0,355099 UGDH ATP6V0D1 0,02521
TGFb-R2 RAMP3 -0,042349 UGDH BTF3 0,065391
TGFb-R2 RHOJ 0,547531 UGDH CALM2 0,367226
TGFb-R2 RPIB9 1,903911 UGDH CASP3 0,245382
TGFb-R2 SMAD2 -0,349989 UGDH CDYL12 0,307307
TGFb-R2 SMAD3 0,024022 UGDH CFH 0,388493
TGFb-R2 TGFb1 -0,978712 UGDH c-Jun -0,006185
TGFb-R2 TGFb-R2 2,036906 UGDH CLF 0,148204
TGFb-R2 TOR3A 0,058657 UGDH CSPG -0,752372
TGFb-R2 UGDH 0,496391 UGDH CXCL12 -0,119975
TOR3A AQP1 -0,847746 UGDH CYR61 -0,148293
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Interaction 
from 
Interaction  
to 
Strenght of 
Interaction 
Interaction 
from 
Interaction  
to 
Strenght of 
Interaction 
UGDH Endothelin1 -0,239631 UGDH PLD 0,312842 
UGDH FGF1 0,781267 UGDH PRG 0,359132 
UGDH FZD4 0,072966 UGDH PRSS23 -0,04542 
UGDH GAPDH 0,207119 UGDH RAMP3 0,064014 
UGDH GCA -0,042267 UGDH RHOJ 0,110438 
UGDH GDI2 0,080081 UGDH RPIB9 -0,756906 
UGDH GNAS2 0,117645 UGDH SMAD2 0,298387 
UGDH GTPBP4 -0,004599 UGDH SMAD3 0,344669 
UGDH HOXA3 0,106492 UGDH TGFb1 0,144615 
UGDH ICAM 0,320821 UGDH TGFb-R2 0,015939 
UGDH KLF6 0,21904 UGDH TOR3A 0,076896 
UGDH NOS3 -0,32921 UGDH UGDH 1,310948 
UGDH PHGDH -0,07038       
 
 
 
Table 5. List of genes comprising the ex vivo set after secondary and tertiary data 
analysis. 
 
ANX2 GAPDH PKN2 
AQP1 GCL PPAP2A 
ATP6V0D1 GDI2 PPP1CB 
ABL2 GL004 PRG1 
ANP32E GNAS PRSS23 
ARF4 GNB2L1 RAD6 
BMX HERC4 RHOJ 
C1S HOXA3/5 RPIB9 
C7 HNRPA3 RHOJ 
CD99 HSPG2 RPIB9 
CDH1 IFTM2 RPL3 
CDYL2 IFTM3 RPL10 
CFH ITM1 RPL13a 
CSPG2 KLF6 SDF1 
CTBP2 LBR SEC23A 
CTTNBP2NL LEPR SFRS12 
CXCR4 LMCD1 SH3D5 
CYR61 LZTFL1 SH3PXD2B 
DAZAP1 MAP4 SIAT7C 
EBF NEGR1 TAF2F 
EPAG9 NESP55 TBCA 
EPHA4 OASL TH1L  
FBN1 OATPB TOR3A 
FN1 OSBPL1A UGDH 
FZD4 OSBPL10 VEGF 
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9. Abbreviations 
 
AGE Advanced glycation end products 
ANGPT2 Angiopoietin-2 
AQP1 Aquaporin 1 
ATP6V0D1 D1 subunit of the transmembrane VO domain of ATPase 
ATPase Adenosine triphosphatase 
BECs Blood vessel endothelial cells 
BTF3 Basic transcription factor 3 
C1S Complement component 1, s subcomponent 
CALM2 Calmodulin 2 
CASP3 Caspase 3 
CDS Coding sequence 
CFH Complement factor H 
CIP Calf intestinal alkaline phosphatase 
CLF Cholesterol lowering factor 
CSPG2 Chondroitin sulfate proteoglycan 2 
Ct Cycle threshold 
CXCL12 Chemokine (CXC motif) ligand 12 
CXCR4 Chemokine (C-X-C motif) receptor 4 
CXCR7 Chemokine (C-X-C motif) receptor 7 
CYR61 Cysteine-rich angiogenic inducer 61 
DAG Diacylglycerol 
DM Diabetes mellitus 
DMA Diabetic microangiopathy 
ECMV encephalomyocarditis virus 
EGFP Enhanced green fluorescent protein 
eNOS Endothelial nitric oxide synthase 
ER Endoplasmatic Reticulum 
ET-1 Endothelin 1 
FGF1 Human fibroblast growth factor 1 
FZD4 Frizzled homolog 4 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
GCA Grancalcin 
GDI2 GDP-dissociation inhibitor 2 
GFP Green fluorescent protein 
GNAS2 Guanine nucleotide binding protein 2 
GTPBP4 GTP binding protein 4 
HOXA3 Homeobox A3 
hTERT Human telomerase reverse transcriptase 
ICAM1 Intercellular adhesion molecule 1 
iHUVECs Immortalized human umbilical vein endothelial cells 
IRES Internal ribosomal entry site 
KLF6 Kruppel-like transcription factor 6 
LDA  Low density array 
MMP9 Matrix metallopeptidase 9 
NAC nascent-polypeptide-associated complex 
NF-κB Nuclear factor-kappa B 
NIR network identification by multiple regression 
NOS3 Nitric oxide synthase 3 
PABP Poly(A)-binding protein 
PAI-1 Plasminogen activator inhibitor-1 
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PARP Poly (ADP-ribose) polymerase 
PBS Phosphate buffered saline 
PBSF Pre-B cell growth stimulating factor 
PCR Polymerase chain reaction 
PDGFA Platelet-derived growth factor alpha polypeptide 
PECAM1 Platelet endothelial cell adhesion molecule  
PHGDH Phosphoglycerate dehydrogenas 
PKC Protein kinase C 
PLD Phospholipase D 
PRSS23 Protease serine 23 
PTC Peptidyl Transferase Center 
RAMP3 Receptor (G protein-coupled) activity modifying protein 3 
RHOJ Ras homolog gene family, member J protein 
ROS  Reactive oxygen species 
RPIB9 Rap2 interacting protein 
RPL3 Ribosomal protein of the large subunit 3 
Rundc3 RUN domain containing 3B 
RVM Relative variance method 
RZPD German Resource Center for Genome Research 
SDF-1 stromal cell-derived factor 1 
SDS sodium dodecyl sulfate or sequence detection software 
SMAD2 Smad family member 2 
SMAD3 Smad family member 3 
SOD1 superoxide dismutase 1 
SRL Sarcin Ricin Loop 
TGF-b Transforming growth factor-beta 
THBD Thrombomodulin 
TOR3A Torsin 3A 
UGDH Uridine diphosphate -glucose dehydrogenase 
VEGF Vascular endothelial growth factor 
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